

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 May 2006 (18.05.2006)

PCT

(10) International Publication Number
WO 2006/052591 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) C07K 16/44 (2006.01)
C07K 16/46 (2006.01)

California 94010 (US). ZAPATA, Gerardo [US/US]; 712 Dalehurst Avenue, San Mateo, California 94403 (US).

(21) International Application Number:
PCT/US2005/039628

(74) Agent: BORDEN, Paula A.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, California 94303 (US).

(22) International Filing Date:
2 November 2005 (02.11.2005)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/981,300 3 November 2004 (03.11.2004) US

(71) Applicant (for all designated States except US): AB-GENIX, INC. [US/US]; 6701 Kaiser Drive, M/S 24, Fremont, California 94555 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): GAZIT-BORN-STEIN, Gadi [US/US]; 521 Del Medio Avenue, Apt. #118, Mountain View, California 94040 (US). SENALDI, Giorgio [IT/US]; 6534-f Cottonwood Circle, Dublin, California 94568 (US). YANG, Xiao-dong [US/US]; 2833 Bryan Street, Palo Alto, California 94306 (US). KEYT, Bruce [US/US]; 1180 Lakeview Drive, Hillsborough,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-PROPERDIN ANTIBODIES, AND METHODS FOR MAKING AND USING SAME



(57) Abstract: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

WO 2006/052591 A2



Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ANTI-PROPERDIN ANTIBODIES, AND METHODS FOR MAKING AND USING SAME**CROSS-REFERENCE**

- [0001] This application claims the benefit of U.S. Patent Application No. 10/981,300, filed November 3, 2004, which application is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

- [0002] The present invention is in the field of antibodies, and in particular, antibodies specific for properdin.

BACKGROUND OF THE INVENTION

- [0003] The complement system provides an early acting mechanism to initiate and amplify the inflammatory response to microbial infection and other acute insults. While complement activation provides a valuable first line of defense against pathogens, inappropriate activation of complement poses potential harm to the host. For instance, the complement system has been implicated in contributing to the pathogenesis of several acute and chronic conditions, including post-cardiopulmonary bypass inflammation, myocardial infarction, stroke, acute respiratory distress syndrome (ARDS), septic shock, transplant rejection, burn injury, multiple sclerosis, myasthenia gravis, and rheumatoid arthritis. It is important to note that while complement may not be the sole cause of pathogenesis in these conditions, complement activation appears to be a major contributing factor and represents a site of therapeutic intervention. This growing recognition of the importance of complement-mediated tissue injury in a variety of disease states underscores the need for effective complement inhibitory drugs.
- [0004] The complement system can be activated through either of two enzymatic cascades, referred to as the classical and alternative pathways. These pathways are shown schematically in Figure 11. Increasing scientific evidence argues that the alternative complement pathway plays a predominant role in eliciting pathology in many acute and chronic disorders.
- [0005] The classical pathway is triggered by antibody bound to a foreign pathogen, and thus requires prior exposure to the pathogen for the generation of specific antibody. There are three plasma proteins specifically involved in the classical pathway: C1, C2, and C4. In contrast, the alternative pathway is spontaneously triggered by foreign or other abnormal surfaces (bacteria, yeast, virally infected cells, or damaged tissue) and is therefore capable of an immediate response. There are also three plasma proteins specific to the alternative pathway: factors B

and D, and properdin. It is important to note that both the classical and alternative complement pathways share common proteins (C3, C5-9) that are involved in the later stages of the activation cascades. The bioactive molecules produced after activation of either complement pathway include the anaphylatoxins C3a and C5a, as well as the terminal complement complex known as C5b-9, also referred to as the membrane attack complex (MAC). These anaphylatoxins initiate a cellular inflammatory response that is beneficial in the case of a pathogenic infection, but is potentially detrimental when inappropriately generated. For example, MAC causes cellular damage through its insertion into cell membranes. Like C3a and C5a, MAC can play a positive role in the destruction of pathogens, but can be deleterious when it attacks host cells.

[0006] Until recently, the role of complement activation in disease pathogenesis was poorly understood. This was due in part, to the absence of specific inhibitors that could be used to directly evaluate the role of complement in animal disease models. The development of a soluble form of the complement receptor 1 (sCR1), an inhibitor of both complement pathways, has shed light on the role complement activation plays in disease pathogenesis. The sCR1 molecule suppresses complement activation by reversibly binding to the C3b and C4b subunits present in the C3- (C4b2a and C3bBb) and C5- convertases (C4b2a3b and (C3b)₂Bb) of the two complement pathways. sCR1 has been demonstrated to be beneficial in animal models of inflammation, ischemia-reperfusion, transplant rejection, trauma, and autoimmune disease.

[0007] Although sCR1 is effective in inhibiting complement *in vivo*, it may have limitations as a therapeutic agent. Based on results from animal studies, the effective therapeutic concentration of sCR1 will be quite high. In addition, the clearance of sCR1 from the bloodstream is surprisingly rapid. Also, because sCR1 blocks both the classical and alternative complement cascades, host defense will be compromised.

[0008] Further evidence of the importance of inappropriate complement activation in disease pathology has been provided by the use of anti-C5 monoclonal antibodies. Anti-C5 antibodies have been shown to be beneficial in murine models of arthritis and immune complex nephritis. In an *ex vivo* model of cardiopulmonary bypass (CPB)-induced inflammation, administration of anti-human C5 monoclonal antibody inhibited leukocyte and platelet activation that normally occurs during such procedures.

[0009] Although anti-C5 antibodies have demonstrated efficacy *in vivo*, there are certain shortcomings of C5 as a therapeutic agent. Firstly, C5 is an abundant plasma protein (~85 µg/ml); therefore, high concentrations of an anti-C5 monoclonal antibody would be required to block C5 activity. In addition, it is important to note that this approach would not block the

formation of C3a, another potent inflammatory mediator. There is accumulating evidence that C3a can initiate potentially detrimental events, including the release of proinflammatory cytokines and prostaglandins from monocytes, histamine release from mast cells, and degranulation of eosinophils.

[0010] Available clinical data suggest that in many acute and chronic injury settings, complement activation is mediated predominantly by the alternative pathway. These findings indicate that it would be advantageous to specifically inhibit alternative pathway-mediated tissue damage in a variety of injury settings, such as post-cardiopulmonary bypass inflammation, myocardial infarction, reperfusion injury, stroke, rheumatoid arthritis, and thermal burns. This would leave aspects of the classical pathway intact to handle immune complex processing and aid in host defense against infection.

[0011] The key enzymatic step of the alternative pathway is mediated by the C3-convertase (C3bBb), which cleaves C3 to yield C3a and C3b. The alternative pathway-specific protein, properdin, has been speculated to play a role in the regulation of the alternative pathway by virtue of its ability to increase the half-life of the C3 and C5 convertase complexes (C3bBb and C3bBbC3b, respectively).

[0012] There is a need in the art for agents that reduce inflammation and other disorders that are mediated, at least in part, by the alternative complement pathway. The present invention addresses this need.

Literature

[0013] Gupta-Bansal et al. (2000) *Mol. Immunol.* 37:191-201; Published U.S. Patent Application No. 20020015701; U.S. Pat. No. 5,770,429; U.S. Pat. No. 6,162,963; U.S. Pat. No. 6,150,584; U.S. Pat. No. 6,114,598; U.S. Pat. No. 6,075,181; Green (1999) *J. Immunol. Methods* 231:11-23; Wells (2000) *Chem Biol* 7:R185-6; and Davis et al. (1999) *Cancer Metastasis Rev* 18(4):421-5; Vuagnat et al. (2000) *Mol. Immunol.* 37:467-478; Perdikoulis et al. (2001) *Biochim. Biophys. Acta* 1548:265-277.

SUMMARY OF THE INVENTION

[0014] The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's),

specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

- [0015] Figure 1 depicts analysis of IgG2 antibodies in an LPS-activation C5b-9 assay.
- [0016] Figure 2 depicts analysis of IgG2 antibodies in a C3b-properdin binding assay.
- [0017] Figure 3 depicts analysis of IgG2 antibodies in an LPS-activation C3c assay.
- [0018] Figure 4 depicts inhibition of membrane attack complex production by anti-properdin antibodies.
- [0019] Figure 5 depicts inhibition of C3a production by anti-properdin antibodies.
- [0020] Figure 6 depicts production of membrane attack complex in the tubing loop model.
- [0021] Figure 7 depicts production of C3a in the tubing loop model.
- [0022] Figure 8 depicts inhibition of C3a production by anti-properdin antibodies (intact antibody, F(ab')₂ fragment, and Fab fragment) in the tubing loop model.
- [0023] Figure 9 depicts inhibition of membrane attack complex by anti-properdin antibodies (intact antibody, F(ab')₂ fragment, and Fab fragment) in an *ex vivo* cardiopulmonary bypass model.
- [0024] Figure 10 depicts inhibition of MAC production by anti-properdin antibodies (intact antibody, F(ab')₂ fragment, and Fab fragment) in an *ex vivo* cardiopulmonary bypass model.
- [0025] Figure 11 depicts schematically two pathways to complement activation.
- [0026] Figure 12 depicts FR1, CDR1, FR2, CDR2, FR3, CDR3, and J regions of exemplary subject antibody light chain variable regions, in comparison with germline ("GL") amino acid sequences. A dash indicates amino acid identity to a give GL sequence; a # symbolizes a gap introduced into a GL sequence.
- [0027] Figure 13 compares nucleotide sequences at V-J junctions ("V sequence"; "J sequence"), the number of N sequences added; as well as the position and length of CDRs, and the CDR1, CDR2, and CDR3 amino acid sequences of various exemplary subject antibody light chain variable regions.
- [0028] Figure 14 depicts FR1, CDR1, FR2, CDR2, FR3, CDR3, and J regions of exemplary subject antibody heavy chain variable regions, in comparison with germline ("GL") amino acid sequences. A dash indicates amino acid identity to a give GL sequence; a # symbolizes a gap introduced into a GL sequence.

- [0029] Figure 15 compares nucleotide sequences at V-D-J junctions ("V sequence"; "D1 sequence"; and "J sequence"), the number of N sequences added; as well as the position and length of CDRs, and the CDR1, CDR2, and CDR3 amino acid sequences of various exemplary subject antibody heavy chain variable regions.
- [0030] Figures 16A-F depict nucleotide sequences of light and heavy chains of exemplary subject antibodies.
- [0031] Figures 17A-C depict amino acid sequences of light and heavy chains of exemplary subject antibodies.

DEFINITIONS

- [0032] The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.
- [0033] The term "isolated protein" referred to herein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
- [0034] The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus. Preferred polypeptides in accordance with the invention comprise the human heavy chain immunoglobulin molecules including variable region amino acid sequences represented by Figures 17A-C (e.g., SEQ ID NOs:04, 08, 12, 16, and 20) and the human kappa light chain immunoglobulin molecules including variable region amino acid sequences represented by Figures 17A-C (e.g., SEQ ID NOs:02, 06, 10, 14, and 18), as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as the kappa light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs thereof.
- [0035] The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence

that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.

[0036] The term "operably linked" as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

[0037] The term "control sequence" as used herein refers to polynucleotide sequences which are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

[0038] The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

[0039] The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides of the invention can be either sense or antisense oligonucleotides.

[0040] The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g.*, LaPlanche et al. *Nucl. Acids Res.* **14**:9081 (1986); Stec et al. *J. Am. Chem. Soc.* **106**:6077 (1984); Stein et

al. *Nucl. Acids Res.* **16**:3209 (1988); Zon et al. *Anti-Cancer Drug Design* **6**:539 (1991); Zon et al. *Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* **90**:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired.

[0041] The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred.

[0042] Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

[0043] The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotides or amino acid sequences may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a "comparison window" to identify and compare local regions of sequence similarity.

[0044] A "comparison window", as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* **2**:482 (1981), by the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* **48**:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* **85**:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks, or MacVector software packages), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

[0045] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See *Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by

reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

[0046] Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

[0047] As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

[0048] As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention,

providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site.

[0049] Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. *Science* **253**:164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize sequence motifs and structural conformations that may be used to define structural and functional domains in accordance with the invention.

[0050] Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogues can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the

naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al. *Nature* **354**:105 (1991), which are each incorporated herein by reference.

[0051] The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxyl-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one biological activity of a corresponding native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogues typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

[0052] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics". Fauchere, *J. Adv. Drug Res.* **15**:29 (1986); Veber and Freidinger *TINS* p.392 (1985); and Evans et al. *J. Med. Chem.* **30**:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --

CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch *Ann. Rev. Biochem.* 61:387 (1992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

[0053] "Antibody" or "antibody peptide(s)" refer to an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab', F(ab')₂, Fv, and single-chain antibodies. An antibody other than a "bispecific" or "bifunctional" antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a polypeptide to a specific binding partner when an excess of antibody reduces the quantity of the polypeptide bound to the specific binding partner by at least about 20%, 40%, 60% or 80%, and more usually greater than about 85% (as measured in an *in vitro* competitive binding assay).

[0054] The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$ and most preferably $\leq 10 \text{ nM}$.

[0055] The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

[0056] As used herein, the terms "label" or "labeled" refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β -

galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0057] The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by *The McGraw-Hill Dictionary of Chemical Terms* (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), incorporated herein by reference).

[0058] As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

[0059] The terms "patient," "mammalian host," and the like are used interchangeably herein, and refer to mammals, including human and veterinary subjects.

[0060] The term "sequence identity" means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison

window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.

[0061] As used herein, the terms “treatment,” “treating,” and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease. “Treatment,” as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease or at risk of acquiring the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.

[0062] The term “a disease or disorder associated with the alternative complement pathway,” as used herein, refers to a disease or disorder caused, directly or indirectly, by activation of the alternative complement pathway, a disease or disorder that is mediated, directly or indirectly, by one or more components of the alternative complement pathway, or a product generated by the alternative complement pathway. The term also refers to a disease or disorder that is exacerbated by one or more components of the alternative complement pathway, or a product generated by the alternative complement pathway.

[0063] Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0064] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated

range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0065] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0066] Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. *See e.g.*, Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0067] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an anti-properdin antibody" includes a plurality of such antibody and reference to "the disease" includes reference to one or more diseases and equivalents thereof known to those skilled in the art, and so forth.

[0068] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

DETAILED DESCRIPTION OF THE INVENTION

[0069] The present invention provides fully human anti-properdin antibodies, and compositions comprising the antibodies. A subject antibody is produced by an antibody-producing cell of a XenoMouse®, a genetically modified mouse that produces antibodies having amino acid sequences of human antibodies, e.g., human framework (FR) and human constant region amino acid sequences.

[0070] XenoMouse® genetically modified mouse strains are genetically engineered mice in which the murine IgH and Igk loci have been functionally replaced by their Ig counterparts on yeast artificial YAC transgenes. These human Ig transgenes can carry the majority of the human variable repertoire and can undergo class switching from IgM to IgG isotypes. The immune system of the xenomouse recognizes administered human antigens as foreign and produces a strong humoral response. The use of XenoMouse® in conjunction with well-established hybridomas techniques, results in fully human IgG mAbs with sub-nanomolar affinities for human antigens (see U.S. Pat. No. 5,770,429, entitled "Transgenic non-human animals capable of producing heterologous antibodies"; U.S. Pat. No. 6,162,963, entitled "Generation of Xenogenetic antibodies"; U.S. Pat. No. 6,150,584, entitled "Human antibodies derived from immunized xenomice"; U.S. Pat. No. 6,114,598, entitled "Generation of xenogeneic antibodies"; and U.S. Pat. No. 6,075,181, entitled "Human antibodies derived from immunized xenomice"; for reviews, see Green, Antibody engineering via genetic engineering of the mouse: XenoMouse® strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, *J. Immunol. Methods* 231:11-23, 1999; Wells, Eek, a XenoMouse®: Abgenix, Inc., *Chem Biol* 2000 Aug;7(8):R185-6; and Davis et al., Transgenic mice as a source of fully human antibodies for the treatment of cancer *Cancer Metastasis Rev* 1999;18(4):421-5).

[0071] A subject antibody is useful in a variety of therapeutic methods. A subject anti-properdin antibody is useful in therapeutic methods for the treatment of diseases mediated, directly or indirectly, by a component of the alternative complement pathway, and/or by a factor generated following activation of the alternative complement pathway.

[0072] A subject anti-properdin antibody avoids problems associated with rodent antibodies, i.e., adverse reactions in humans, such as hypersensitivity reactions, including urticaria, dyspnea, hypotension, anaphylaxis, and the like.

ANTI-PROPERDIN ANTIBODIES

[0073] The present invention provides fully human anti-properdin antibodies, and compositions comprising the antibodies. A subject antibody is produced by an antibody-producing cell of a Xenomouse®, a genetically modified mouse that produces antibodies having amino acid sequences of human antibodies, e.g., human framework (FR) and human constant region amino acid sequences.

Properdin

[0074] Properdin polypeptides are known in the art. For example, the amino acid sequences of human and mouse properdin are found in the GenBank database under the following accession numbers: for human properdin, see, e.g., GenBank Accession Nos. AAA36489, NP_002612, AAH15756, AAP43692, S29126, CAA40914; for mouse properdin, see, e.g., GenBank Accession Nos. P11680, and S05478. Human properdin is a 469 amino acid protein that includes a signal peptide (amino acids 1-28), and six, non-identical thrombospondin type 1 repeats (TSR) of about 60 amino acids each, as follows: amino acids 80-134 (TSR1), amino acids 139-191 (TSR2), amino acids 196-255 (TSR3), amino acids 260-313 (TSR4), amino acids 318-377 (TSR5), and amino acids 382-462 (TSR6). Properdin is formed by oligomerization of a rod-like monomer into cyclic dimers, trimers, and tetramers.

Antibody Activities

[0075] A subject anti-properdin antibody exhibits one or more of the following activities: (1) inhibits binding of properdin to C3b; (2) inhibits oligomerization of properdin monomers; (3) reduces the level and/or production of a component of the alternative complement pathway, or a factor produced by action of a component of the alternative complement pathway; (4) reduces formation of membrane attack complex (MAC); (5) reduces formation of anaphylatoxins, e.g., C3a and/or C5a; and (6) reduces formation of C3c.

[0076] In some embodiments, a subject antibody binds to an epitope within a TSR of properdin, e.g., a subject antibody binds to an epitope within TSR1, TSR2, TSR3, TSR4, TSR5, or TSR6. In some embodiments, a subject antibody binds to two or more TSRs of a properdin polypeptide, e.g., where an epitope is shared between or among TSRs, and where shared epitopes may, but need not, be identical in amino acid sequence.

[0077] In some embodiments, a subject antibody inhibits binding of properdin to C3b. In these embodiments, a subject antibody effects an at least about 20%, at least about 30%, at least

about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, inhibition of binding of properdin to C3b.

[0078] Whether a subject antibody inhibits properdin/C3b binding can be determined by using any of a number of well-known assays to detect protein-protein binding, including, but not limited to, a fluorescence resonance energy transfer (FRET) assay, a bioluminescence resonance energy transfer (BRET) assay, a fluorescence quenching assay; a fluorescence anisotropy assay; an immunological assay; and an assay involving binding of a detectably labeled protein to an immobilized protein. Immunological assays, and assays involving binding of a detectably labeled protein to an immobilized protein can be arranged in a variety of ways. For example, C3b is immobilized on a solid support, and binding of properdin to C3b in the presence of a test antibody is detected. The properdin can be detectably labeled, either directly or indirectly, as described in Example 1.

[0079] A subject antibody inhibits the level and/or production in a mammalian host of one or more components of the alternative complement pathway and/or one or more factors produced by action of one or more components of the alternative complement pathway. Exemplary, non-limiting examples of components and factors that are reduced include MAC (C5b-9), C3c, and anaphylatoxins, such as C3a and C5a, and the like. A subject antibody reduces the levels of one or more components of the alternative complement pathway and/or one or more factors produced by action of one or more components of the alternative complement pathway by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, compared to the level of the component or factor in the absence of the subject antibody.

[0080] In some embodiments, a subject antibody reduces the level and/or production of MAC in a mammalian host. In these embodiments, a subject antibody reduces formation of MAC by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, compared to the level of MAC in a mammalian host not treated with the antibody. Whether a subject antibody reduces formation of MAC can be readily determined using any known assay, e.g., an *in vitro* assay such as described in Example 1. For example, human serum is contacted, in the presence or absence of a test antibody, with immobilized lipopolysaccharide (LPS) to activate complement, which results in covalent attachment of C5b-9 to the immobilized LPS. LPS-bound C5b-9 is detected using an antibody specific for C5b-9.

[0081] In some embodiments, a subject antibody reduces the level and/or production of an anaphylatoxin, such as C3a and C5a, in a mammalian host. In these embodiments, a subject

antibody reduces formation of an anaphylatoxin by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, compared to the level of an anaphylatoxin in a mammalian host not treated with the antibody. Whether the level of an anaphylatoxin is reduced is readily determined using any known method, including the methods described in the Examples.

Detectable labels

[0082] In some embodiments, a subject antibody is detectably labeled. Detectable labels include, but are not limited to, fluorescent proteins; enzymes (e.g., β -galactosidase, luciferase, horse radish peroxidase, etc.); radioisotopes, e.g., ^{32}P , ^{35}S , ^3H ; *etc.*; fluorescers, e.g., fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, and fluorescent proteins; chemiluminescers; specific binding molecules; particles, e.g. magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. Suitable fluorescent proteins include those described in Matz et al. ((1999) *Nature Biotechnology* 17:969-973), a green fluorescent protein from any species or a derivative thereof; e.g., a GFP from another species such as *Renilla reniformis*, *Renilla mulleri*, or *Ptilosarcus guernyi*, as described in, e.g., WO 99/49019 and Peelle et al. (2001) *J. Protein Chem.* 20:507-519; "humanized" recombinant GFP (hrGFP) (Stratagene); a GFP from *Aequoria victoria* or fluorescent mutant thereof, e.g., as described in U.S. Patent No. 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445; 5,874,304.

Antibody Structure

[0083] The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxyl-terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. *See generally, Fundamental Immunology* Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site.

- [0084] Thus, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same.
- [0085] The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat *Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk *J. Mol. Biol.* **196**:901-917 (1987); Chothia et al. *Nature* **342**:878-883 (1989).
- [0086] In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% amino acid sequence identity to any one of SEQ ID NOs:02, 06, 10, 14, and 18, as shown in Figures 17A-C. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence that differs from any one of SEQ ID NOs:02, 06, 10, 14, and 18 by only one, two, three, four, five, six, seven, eight, nine, or ten amino acids. Those of ordinary skill in the art can readily determine which amino acids in a light chain variable region can be altered. For example, by comparing the amino acid sequences of light chain variable regions of antibodies with the same specificity, those skilled in the art can determine which amino acids can be altered without altering the specificity. See, e.g., Figure 12 for a comparison of CDR amino acid sequences of exemplary anti-properdin antibody light chains. Furthermore, whether the specificity is altered can be readily determined using an antigen binding assay. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:02, 06, 10, 14, and 18.
- [0087] In some embodiments, a subject antibody comprises a heavy chain comprising an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% amino acid sequence identity to any one of SEQ ID NOs:04, 08, 12, 16, or 20, as shown in Figures 17A-C. In some embodiments, a subject antibody comprises a heavy chain comprising an amino acid sequence that differs from any one of SEQ ID NOs:04, 08, 12, 16, or 20 by only one, two, three, four, five, six, seven, eight, nine, or ten amino acids. Those of ordinary skill in the art can readily determine which amino acids in a heavy chain variable region can be altered. For example, by comparing the

amino acid sequences of heavy chain variable regions of antibodies with the same specificity, those skilled in the art can determine which amino acids can be altered without altering the specificity. See, e.g., Figure 14 for a comparison of CDR amino acid sequences of exemplary anti-properdin antibody heavy chains. Furthermore, whether the specificity is altered can be readily determined using an antigen binding assay. In some embodiments, a subject antibody comprises a heavy chain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:04, 08, 12, 16, or 20.

[0088] In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:02, 06, 10, 14, and 18; and a heavy chain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:04, 08, 12, 16, or 20. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO:02 and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO:04. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO:06 and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO:08. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO:10 and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO:12. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO:14 and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO:16. In some embodiments, a subject antibody comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO:18 and a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO:20.

[0089] A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann *Clin. Exp. Immunol.* **79**: 315-321 (1990), Kostelny et al. *J. Immunol.* **148**:1547-1553 (1992). Production of bispecific antibodies can be a relatively labor intensive process compared with production of conventional antibodies and yields and degree of purity are generally lower for bispecific antibodies. Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv).

Human Antibodies and Humanization of Antibodies

[0090] Human antibodies avoid certain of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived

proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a patient. In order to avoid the utilization of murine or rat derived antibodies, it has been postulated that one can develop humanized antibodies or generate fully human antibodies through the introduction of human antibody function into a rodent so that the rodent would produce fully human antibodies.

Human Antibodies

[0091] The ability to clone and reconstruct megabase-sized human loci in YACs and to introduce them into the mouse germline provides a powerful approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. Furthermore, the utilization of such technology for substitution of mouse loci with their human equivalents could provide unique insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.

[0092] An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated offers the opportunity to study the mechanisms underlying programmed expression and assembly of antibodies as well as their role in B-cell development. Furthermore, such a strategy could provide an ideal source for production of fully human monoclonal antibodies (Mabs) - an important milestone towards fulfilling the promise of antibody therapy in human disease. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which require repeated antibody administrations.

[0093] One approach towards this goal was to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci in anticipation that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve the large variable gene diversity as well as the proper regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should yield high affinity antibodies against any antigen of interest, including human antigens. Using the

hybridoma technology, antigen-specific human Mabs with the desired specificity could be readily produced and selected.

[0094] This general strategy was demonstrated in connection with our generation of the first XenoMouse™ strains as published in 1994. *See* Green et al. *Nature Genetics* 7:13-21 (1994). The XenoMouse™ strains were engineered with yeast artificial chromosomes (YACs) containing 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain locus and kappa light chain locus, respectively, which contained core variable and constant region sequences. *Id.* The human Ig containing YACs proved to be compatible with the mouse system for both rearrangement and expression of antibodies and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development, to produce an adult-like human repertoire of fully human antibodies, and to generate antigen-specific human Mabs. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization. The work of Green et al. was recently extended to the introduction of greater than approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and kappa light chain loci, respectively, to produce XenoMouse™ mice. *See* Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996, the disclosures of which are hereby incorporated by reference.

[0095] Such approach is further discussed and delineated in U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. *See also* Mendez et al. *Nature Genetics* 15:146-156 (1997) and Green and Jakobovits *J. Exp. Med.* 188:483-495 (1998). *See also* European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety.

[0096] In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second

constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al. and U.S. Patent Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 each to Lonberg and Kay, U.S. Patent No. 5,591,669 and 6,023,010 to Krimpenfort and Berns, U.S. Patent Nos. 5,612,205, 5,721,367, and 5,789,215 to Berns et al., and U.S. Patent No. 5,643,763 to Choi and Dunn, and GenPharm International U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994, the disclosures of which are hereby incorporated by reference. *See also* European Patent No. 0 546 073 B1, International Patent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent No. 5,981,175, the disclosures of which are hereby incorporated by reference in their entirety. *See further* Taylor et al., 1992, Chen et al., 1993, Tuailon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuailon et al., (1995), Fishwild et al., (1996), the disclosures of which are hereby incorporated by reference in their entirety.

[0097] The inventors of Surani et al., cited above and assigned to the Medical Research Counsel (the "MRC"), produced a transgenic mouse possessing an Ig locus through use of the minilocus approach. The inventors on the GenPharm International work, cited above, Lonberg and Kay, following the lead of the present inventors, proposed inactivation of the endogenous mouse Ig locus coupled with substantial duplication of the Surani et al. work.

[0098] An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals. Commensurately, however, a significant disadvantage of the minilocus approach is that, in theory, insufficient diversity is introduced through the inclusion of small numbers of V, D, and J genes. Indeed, the published work appears to support this concern. B-cell development and antibody production of animals produced through use of the minilocus approach appear stunted. Therefore, research surrounding the present invention has consistently been directed towards the introduction of large portions of the Ig locus in order to achieve greater diversity and in an effort to reconstitute the immune repertoire of the animals.

[0099] Kirin has also demonstrated the generation of human antibodies from mice in which, through microcell fusion, large pieces of chromosomes, or entire chromosomes, have been introduced. See European Patent Application Nos. 773 288 and 843 961, the disclosures of which are hereby incorporated by reference.

[00100] Human anti-mouse antibody (HAMA) responses have led the industry to prepare chimeric or otherwise humanized antibodies. While chimeric antibodies have a human constant region and a murine variable region, it is expected that certain human anti-chimeric antibody (HACA) responses will be observed, particularly in chronic or multi-dose utilizations of the antibody. Thus, it would be desirable to provide fully human antibodies against properdin in order to vitiate concerns and/or effects of HAMA or HACA response.

Humanization and Display Technologies

[00101] As was discussed above in connection with human antibody generation, there are advantages to producing antibodies with reduced immunogenicity. To a degree, this can be accomplished in connection with techniques of humanization and display techniques using appropriate libraries. It will be appreciated that murine antibodies or antibodies from other species can be humanized or primatized using techniques well known in the art. See e.g., Winter and Harris *Immunol Today* **14**:43-46 (1993) and Wright et al. *Crit. Reviews in Immunol.* **12**:125-168 (1992). The antibody of interest may be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (see WO 92/02190 and U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,761, 5,693,792, 5,714,350, and 5,777,085). Also, the use of Ig cDNA for construction of chimeric immunoglobulin genes is known in the art (Liu et al. *P.N.A.S.* **84**:3439 (1987) and *J.Immunol.* **139**:3521 (1987)). mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest may be amplified by the polymerase chain reaction using specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes may be found in Kabat et al. (1991) *Sequences of Proteins of Immunological Interest*, N.I.H. publication no. 91-3242. Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1, IgG3 and IgG4. Either of the human light chain constant regions, kappa or lambda, may be used. The chimeric, humanized antibody is then expressed by conventional methods.

- [00102] Antibody fragments, such as Fv, F(ab')₂ and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab')₂ fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.
- [00103] Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.
- [00104] Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g. SV-40 early promoter, (Okayama et al. *Mol. Cell. Bio.* **3**:280 (1983)), Rous sarcoma virus LTR (Gorman et al. *P.N.A.S.* **79**:6777 (1982)), and moloney murine leukemia virus LTR (Grosschedl et al. *Cell* **41**:885 (1985)). Also, as will be appreciated, native Ig promoters and the like may be used.
- [00105] Further, human antibodies or antibodies from other species can be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art. Wright and Harris, *supra.*, Hanes and Plutchau *PNAS USA* **94**:4937-4942 (1997) (ribosomal display), Parmley and Smith *Gene* **73**:305-318 (1988) (phage display), Scott *TIBS* **17**:241-245 (1992), Cwirla et al. *PNAS USA* **87**:6378-6382 (1990), Russel et al. *Nucl. Acids Research* **21**:1081-1085 (1993), Hoganboom et al. *Immunol. Reviews* **130**:43-68 (1992), Chiswell and McCafferty *TIBTECH* **10**:80-84 (1992), and U.S. Patent No. 5,733,743. If display technologies are utilized to produce antibodies that are not human, such antibodies can be humanized as described above.

[00106] Using these techniques, antibodies can be generated to properdin-expressing cells, properdin itself, forms of properdin epitopes or peptides thereof, and expression libraries thereto (*see e.g.* U.S. Patent No. 5,703,057) which can thereafter be screened as described above for the activities described above.

Additional Criteria for Antibody Therapeutics

[00107] As discussed herein, the function of a subject anti-properdin antibody appears important to at least a portion of its mode of operation. By function, we mean, by way of example, the activity of the anti-properdin antibody in inhibiting the alternative complement pathway, e.g., a subject anti-properdin antibody exhibits one or more of the following properties: (1) inhibits binding of properdin to C3b; (2) inhibits oligomerization of properdin monomers; (3) reduces formation of a component of the alternative complement pathway, or a factor produced by action of a component of the alternative complement pathway; (4) reduces formation of membrane attack complex (MAC); (5) reduces formation of anaphylatoxins, e.g., C3a and/or C5a; and (6) reduces formation of C3c.

[00108] A subject antibody will in some embodiments comprise an IgG₁ human heavy chain constant region; in other embodiments an IgG₂ human heavy chain constant region; and in other embodiments an IgG₃ human heavy chain constant region. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather, the antibody as generated can possess any isotype and the antibody can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (*see e.g.*, U.S. Patent No. 4,816,397), cell-cell fusion techniques (*see e.g.*, U.S. Patent Nos. 5,916,771 and 6,207,418), among others.

[00109] In the cell-cell fusion technique, a myeloma or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.

[00110] By way of example, the anti-properdin antibody discussed herein is a human anti-properdin IgG₂ antibody. If such antibody possessed desired binding to a properdin polypeptide or epitope or fragment thereof, it could be readily isotype switched to generate a human IgM, human IgG₁, or human IgG₃ isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity).

[00111] Accordingly, as antibody candidates are generated that meet desired "structural" attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching.

Design and Generation of Other Therapeutics

[00112] In accordance with the present invention and based on the activity of the antibodies that are produced and characterized herein with respect to inhibition of the alternative complement pathway, the design of other therapeutic modalities beyond antibody moieties is facilitated. Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.

[00113] In connection with the generation of advanced antibody therapeutics, where complement fixation is a desirable attribute, it may be possible to sidestep the dependence on complement for cell killing through the use of bispecifics, immunotoxins, or radiolabels, for example.

[00114] For example, in connection with bispecific antibodies, bispecific antibodies can be generated that comprise (i) two antibodies one with a specificity to properdin and another to a second molecule that are conjugated together, (ii) a single antibody that has one chain specific to properdin and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to properdin and the other molecule. Such bispecific antibodies can be generated using techniques that are well known for example, in connection with (i) and (ii) *see e.g.*, Fanger et al. *Immunol Methods* **4**:72-81 (1994) and Wright and Harris, *supra.* and in connection with (iii) *see e.g.*, Traunecker et al. *Int. J. Cancer (Suppl.)* **7**:51-52 (1992). In each case, the second specificity can be made to the heavy chain activation receptors, including, without limitation, CD16 or CD64 (*see e.g.*, Deo et al. **18**:127 (1997)) or CD89 (*see e.g.*, Valerius et al. *Blood* **90**:4485-4492 (1997)). Bispecific antibodies prepared in accordance with the foregoing would be likely to kill cells expressing properdin and particularly those cells in which the anti-properdin antibodies of the invention are effective.

[00115] In connection with immunotoxins, antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. *See e.g.*, Vitetta *Immunol Today* **14**:252 (1993). *See also* U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. *See e.g.*, Junghans et al. in *Cancer Chemotherapy and Biotherapy* 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). *See also* U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing properdin, and particularly those cells in which the antibodies of the invention are effective.

[00116] In connection with the generation of therapeutic peptides, through the utilization of structural information related to properdin and antibodies thereto, such as the antibodies of the invention (as discussed below in connection with small molecules) or screening of peptide libraries, therapeutic peptides can be generated that are directed against properdin. Design and screening of peptide therapeutics is discussed in connection with Houghten et al. *Biotechniques* **13**:412-421 (1992), Houghten *PNAS USA* **82**:5131-5135 (1985), Pinalla et al. *Biotechniques* **13**:901-905 (1992), Blake and Litzi-Davis *BioConjugate Chem.* **3**:510-513 (1992).

Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.

[00117] Assuming that the properdin molecule (or a form, such as a splice variant or alternate form) is functionally active in a disease process, it will also be possible to design gene and antisense therapeutics thereto through conventional techniques. Such modalities can be utilized for modulating the function of properdin. In connection therewith the antibodies of the present invention facilitate design and use of functional assays related thereto. A design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444. Design and strategies for gene therapy are well known. However, in particular, the use of gene therapeutic techniques involving intrabodies could prove to be particularly advantageous. See e.g., Chen et al. *Human Gene Therapy* **5**:595-601 (1994) and Marasco *Gene Therapy* **4**:11-15 (1997). General design of and considerations related to gene therapeutics is also discussed in International Patent Application No. WO 97/38137.

[00118] Small molecule therapeutics can also be envisioned in accordance with the present invention. Drugs can be designed to modulate the activity of properdin based upon the present invention. Knowledge gleaned from the structure of the properdin molecule and its interactions with other molecules in accordance with the present invention, such as the antibodies of the invention, properdin, and others can be utilized to rationally design additional therapeutic modalities. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with the molecule or specific forms thereof which can be used to modify or modulate the activity of properdin. Such structures can be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al. *Genetically Engineered Human Therapeutic Drugs* (Stockton Press, NY (1988)). Further,

combinatorial libraries can be designed and synthesized and used in screening programs, such as high throughput screening efforts.

Therapeutic Administration and Formulations

[00119] It will be appreciated that the therapeutic entities in accordance with the invention will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. *See also* Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." *Regul. Toxicol. Pharmacol.* **32(2)**:210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." *Int. J. Pharm.* **203(1-2)**:1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." *J Pharm Sci.* **89(8)**:967-78 (2000), Powell et al. "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

Preparation of Antibodies

[00120] Antibodies in accordance with the invention are preferably prepared through the utilization of a transgenic mouse that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine, antibodies. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents, applications, and references disclosed in the Background, herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996 and

International Patent Application Nos. WO 98/24893, published June 11, 1998 and WO 00/76310, published December 21, 2000, the disclosures of which are hereby incorporated by reference. *See also* Mendez et al. *Nature Genetics* **15**:146-156 (1997), the disclosure of which is hereby incorporated by reference.

[00121] Through use of such technology, we have produced fully human monoclonal antibodies to a variety of antigens. Essentially, we immunize XenoMouse® lines of mice with an antigen of interest, recover lymphatic cells (such as B-cells) from the mice that express antibodies, fuse such recovered cells with a myeloid-type cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. We utilized these techniques in accordance with the present invention for the preparation of antibodies specific to properdin. Herein, we describe the production of multiple hybridoma cell lines that produce antibodies specific to properdin. Further, we provide a characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies.

[00122] The hybridoma cell lines discussed herein are readily generated by those of ordinary skill in the art, given the guidance provided herein. Each of the antibodies produced by the subject cell lines are either fully human IgG2 or IgG4 heavy chains with human kappa light chains. In general, antibodies in accordance with the invention possess very high affinities, typically possessing Kd's of from about 10^{-9} through about 10^{-11} M, when measured by either solid phase and solution phase.

[00123] As will be appreciated, antibodies in accordance with the present invention can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used for transformation of a suitable mammalian host cell. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

[00124] Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive properdin binding properties.

[00125] The results demonstrated in accordance with the present invention indicate that antibodies in accordance with the present invention possess certain qualities that may make the present antibodies more efficacious than currently available antibodies against properdin. Antibodies in accordance with the invention have high affinities and appear efficacious in inhibiting the alternative complement pathway, and therefore in treating disorders associated with and/or mediated by the alternative complement pathway.

POLYNUCLEOTIDES, VECTORS, AND HOST CELLS

[00126] The present invention further provides polynucleotides, including isolated polynucleotides, that comprise a nucleotide sequence encoding a subject antibody. The present invention further provides vectors, including expression vectors, comprising a subject polynucleotide. The present invention further provides host cells, including isolated host cells, that comprise a subject polynucleotide or a subject vector. In many embodiments, a subject host cell produces a subject antibody.

[00127] The present invention provides polynucleotides (“nucleic acids”), including isolated polynucleotides, that comprise a nucleotide sequence encoding a subject antibody, as well as compositions comprising such nucleic acids. By nucleic acid composition is meant a composition comprising a sequence of DNA having an open reading frame that encodes a subject antibody and is capable, under appropriate conditions, of being expressed as a subject antibody.

[00128] Nucleic acids encoding a subject antibody may be cDNA or genomic DNA or a fragment thereof. The term gene shall be intended to mean the open reading frame encoding specific antibodies of the subject invention, and introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome.

[00129] The term “cDNA” as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a protein according to the subject invention.

[00130] In some embodiments, a subject nucleic acid encoding a subject antibody light chain comprises a nucleotide sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% nucleotide sequence identity to any of SEQ ID NOs:01, 05, 09, 13, and 17, as shown in Figures 16A-F. In some embodiments, a subject nucleic acid encoding a subject antibody light chain differs by only one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides from any of SEQ ID NOs:01, 05, 09, 13, and 17. In some embodiments, a subject nucleic acid encoding a subject antibody light chain comprises a nucleotide sequence as set forth in any of SEQ ID NOs:01, 05, 09, 13, and 17.

[00131] In some embodiments, a subject nucleic acid encoding a subject antibody heavy chain comprises a nucleotide sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% nucleotide sequence identity to any of SEQ ID NOs:03, 07, 11, 15, and 19, as shown in Figures 16A-F. In some embodiments, a subject nucleic acid encoding a subject antibody heavy chain differs by only one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides from any of SEQ ID NOs:03, 07, 11, 15, and 19. In some embodiments, a subject nucleic acid encoding a subject antibody heavy chain comprises a nucleotide sequence as set forth in any of SEQ ID NOs:03, 07, 11, 15, and 19.

[00132] Exemplary, non-limiting antibodies are as follows: (1) an antibody designated GL001H8_7 comprising an antibody light chain variable region having an amino acid sequence as set forth in SEQ ID NO:02 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:01, an antibody heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:04 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:03; (2) an antibody designated GL001H8_14 comprising an antibody light chain variable region having an amino acid sequence as set forth in SEQ ID NO:06 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:05, an antibody heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:08 and encoded by a nucleic acid having a nucleotide sequence as set

forth in SEQ ID NO:07; (3) an antibody designated GL001H8_11 comprising an antibody light chain variable region having an amino acid sequence as set forth in SEQ ID NO:10 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:09, an antibody heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:12 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:11; (4) an antibody designated GL001 H1_6_2 comprising an antibody light chain variable region having an amino acid sequence as set forth in SEQ ID NO:14 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:13, an antibody heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:16 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:15; and (5) an antibody designated GL001 H1_12_1 comprising an antibody light chain variable region having an amino acid sequence as set forth in SEQ ID NO:18 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:17, an antibody heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:20 and encoded by a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:19.

[00133] A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include the 3' and 5' untranslated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

[00134] The subject nucleic acid molecules may also be provided as part of a vector (e.g., a "construct"), a wide variety of which are known in the art and need not be elaborated upon herein. Vectors include, but are not limited to, plasmids; cosmids; viral vectors; artificial chromosomes (YAC's, BAC's, etc.); mini-chromosomes; and the like. Vectors are amply described in numerous publications well known to those in the art, including, e.g., Short Protocols in Molecular Biology, (1999) F. Ausubel, et al., eds., Wiley & Sons. Vectors may provide for expression of the subject nucleic acids, may provide for propagating the subject nucleic acids, or both.

- [00135] The subject genes are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a sequence or fragment thereof of the subject genes, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.
- [00136] The subject nucleic acid compositions find use in the preparation of all or a portion of a subject antibody. For expression, an expression cassette may be employed. The expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. These control regions may be native to a gene encoding the subject peptides, or may be derived from exogenous sources.
- [00137] Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for the production of fusion proteins, where the exogenous fusion peptide provides additional functionality, *i.e.* increased protein synthesis, stability, reactivity with defined antisera, an enzyme marker, *e.g.* β -galactosidase, etc.
- [00138] A subject antibody may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, *e.g.* COS 7 cells, may be used as the expression host cells. In some situations, it is desirable to express the nucleic acid in eukaryotic cells, where the encoded protein will benefit from native folding and post-translational modifications.
- [00139] The present invention provides host cells, including isolated host cells, that comprise a subject polynucleotide or a subject vector. In many embodiments, a subject host cell is a eukaryotic host cell that is capable of producing antibody after being genetically modified with a subject expression vector. In many embodiments, a subject host cell is a hybridoma cell that is produced by fusing an antibody-producing cell from a Xenomouse® that has been immunized with properdin with a cell that serves as a fusion partner, *e.g.*, a myeloma fusion partner that does not produce antibody.

TREATMENT METHODS

[00140] The present invention provides therapeutic methods involving use of a subject anti-properdin antibody in therapeutic methods carried out on a mammalian host, including methods of inhibiting the alternative complement pathway, including methods of reducing the level of a polypeptide generated following activation of the alternative complement pathway; methods of reducing the level of membrane attack complex (MAC); methods of reducing the level of an anaphylatoxin; methods of reducing the level of C3c; and methods of treating a disease or disorder mediated by the alternative complement pathway. The methods generally involve administering to a mammalian subject in need thereof an effective amount of a subject antibody.

[00141] An “effective amount” of a subject antibody is an amount that is effective to reduce the production and/or level of a polypeptide generated following activation of the alternative complement pathway by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more.

[00142] A subject antibody is administered to an individual in a formulation with a pharmaceutically acceptable excipient(s). A wide variety of pharmaceutically acceptable excipients are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, A. Gennaro (2000) “Remington: The Science and Practice of Pharmacy,” 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H.C. Ansel et al., eds., 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A.H. Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc.

[00143] The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.

[00144] In the subject methods, a subject antibody may be administered to the host using any convenient means capable of resulting in the desired therapeutic effect. Thus, the antibody can be incorporated into a variety of formulations for therapeutic administration. More particularly, a subject antibody can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets,

capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.

[00145] As such, administration of a subject antibody can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, subcutaneous, intramuscular, transdermal, intranasal, pulmonary, intratracheal, etc., administration.

[00146] Subcutaneous administration of a subject antibody is accomplished using standard methods and devices, e.g., needle and syringe, a subcutaneous injection port delivery system, and the like. Intramuscular administration is accomplished by standard means, e.g., needle and syringe, continuous delivery system, etc.

[00147] In some embodiments, a subject antibody is delivered by a continuous delivery system. The term "continuous delivery system" is used interchangeably herein with "controlled delivery system" and encompasses continuous (e.g., controlled) delivery devices (e.g., pumps) in combination with catheters, injection devices, and the like, a wide variety of which are known in the art. Mechanical or electromechanical infusion pumps can also be suitable for use with the present invention. Examples of such devices include those described in, for example, U.S. Pat. Nos. 4,692,147; 4,360,019; 4,487,603; 4,360,019; 4,725,852; 5,820,589; 5,643,207; 6,198,966; and the like. In general, the present methods of drug delivery can be accomplished using any of a variety of refillable, pump systems. Pumps provide consistent, controlled release over time.

[00148] In pharmaceutical dosage forms, the agents may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way limiting.

[00149] A subject antibody can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

[00150] Unit dosage forms for injection or intravenous administration may comprise the inhibitor(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.

[00151] The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a subject antibody calculated in an amount sufficient to produce the desired effect

in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the unit dosage forms of the present invention depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

[00152] A subject antibody is administered to an individual at a frequency and for a period of time so as to achieve the desired therapeutic effect. For example, a subject antibody is administered once per month, twice per month, three times per month, every other week (qow), once per week (qw), twice per week (biw), three times per week (tiw), four times per week, five times per week, six times per week, every other day (qod), daily (qd), twice a day (qid), or three times a day (tid), or substantially continuously, or continuously, over a period of time ranging from about one day to about one week, from about two weeks to about four weeks, from about one month to about two months, from about two months to about four months, from about four months to about six months, or longer.

Combination therapy

[00153] A subject antibody will in some embodiments be administered in an effective amount in combination therapy with a second therapeutic agent. Suitable second therapeutic agents include, but are not limited to, anti-inflammatory agents; agents used for the treatment of cardiovascular disorders; steroidal anti-inflammatory agents; and the like.

[00154] Suitable anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs (NSAIDs) acetaminophen, salicylate, acetyl-salicylic acid (aspirin, diflunisal), ibuprofen, Motrin, Naprosyn, Nalfon, and Trilisate, indomethacin, glucametacine, acemetacin, sulindac, naproxen, piroxicam, diclofenac, benoxaprofen, ketoprofen, oxaprozin, etodolac, ketorolac tromethamine, ketorolac, nabumetone, and the like, and mixtures of two or more of the foregoing. Other suitable anti-inflammatory agents include methotrexate.

[00155] Suitable steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, and triamcinolone.

[00156] Suitable agents for cardiovascular indications include GP IIb-IIIa inhibitors such as Integrilin® (eptifibatide); aprotinin; ReoPro® (abciximab); and the like.

[00157] Suitable second therapeutic agents include beta adrenergics which include bronchodilators including albuterol, isoproterenol sulfate, metaproterenol sulfate, terbutaline sulfate, pirbuterol acetate and salmeterol formoterol; steroids including beclomethasone dipropionate, flunisolide, fluticasone, budesonide and triamcinolone acetonide. Anti-inflammatory drugs used in connection with the treatment of respiratory diseases include

steroids such as beclomethasone dipropionate, triamcinolone acetonide, flunisolide and fluticasone. Other suitable anti-inflammatory drugs include cromoglycates such as cromolyn sodium. Other respiratory drugs which would qualify as bronchodilators include anticholinergics including ipratropium bromide. Anti-histamines include, but are not limited to, diphenhydramine, carbinoxamine, clemastine, dimenhydrinate, prylamine, tripeleminamine, chlorpheniramine, brompheniramine, hydroxyzine, cyclizine, meclizine, chlorcyclizine, promethazine, doxylamine, loratadine, and terfenadine. Particular anti-histamines include rhinolast (Astelin), claratyne (Claritin), claratyne D (Claritin D), telfast (Allegra), zyrtec, and beconase.

[00158] In some embodiments, a subject antibody is administered concurrently with a second therapeutic agent. As used herein, the term “concurrently” indicates that the subject antibody and the second therapeutic agent are administered separately and are administered within about 5 seconds to about 15 seconds, within about 15 seconds to about 30 seconds, within about 30 seconds to about 60 seconds, within about 1 minute to about 5 minutes, within about 5 minutes to about 15 minutes, within about 15 minutes to about 30 minutes, within about 30 minutes to about 60 minutes, within about 1 hour to about 2 hours, within about 2 hours to about 6 hours, within about 6 hours to about 12 hours, within about 12 hours to about 24 hours, or within about 24 hours to about 48 hours of one another.

[00159] In some embodiments, a subject antibody is administered during the entire course of treatment with the second therapeutic agent. In other embodiments, a subject antibody is administered for a period of time that is overlapping with that of the treatment with the second therapeutic agent, e.g., the antibody treatment can begin before the treatment with the second therapeutic agent begins and end before the treatment with the second therapeutic agent ends; the antibody treatment can begin after the treatment with the second therapeutic agent begins and end after the antibody treatment ends; the antibody treatment can begin after the treatment with the second therapeutic agent begins and end before the treatment with the second therapeutic agent ends; or antibody treatment can begin before the treatment with the second therapeutic agent begins and end after the treatment with the second therapeutic agent ends.

SUBJECTS SUITABLE FOR TREATMENT

[00160] Subjects suitable for treatment with a subject method include individuals suffering from one or more of the following disorders: post-cardiopulmonary bypass inflammation, myocardial infarction, stroke, acute respiratory distress syndrome (ARDS), septic shock, transplant rejection, burn injury, multiple sclerosis, myasthenia gravis, cardiovascular disorders, and rheumatoid arthritis. Subjects suitable for treatment with a subject method also

include individuals suffering from any inflammatory disorder, including, but not limited to, systemic lupus erythematosus, membranous nephritis, pemphigoid, dermatomyositis, and anti-phospholipid syndrome. Subjects suitable for treatment also include subjects undergoing renal dialysis.

Incorporation by Reference

[00161] All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety. In addition, the following references are also incorporated by reference herein in their entirety, including the references cited in such references:

Equivalents

[00162] The foregoing description and Examples detail certain preferred embodiments of the invention and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof.

EXAMPLES

[00163] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s, second(s); min, minute(s); hr, hour(s); and the like.

Example 1: Preparation and characterization of anti-properdin monoclonal antibodies

Summary

[00164] The aim of this study was to identify fully human monoclonal antibodies (MoAbs) that bind to human properdin with high affinity and block the complement alternative pathway. Since it is important that these MoAbs do not themselves trigger inflammation via activation of

complement or Fcγ receptors, IgG2 and IgG4 XenoMouse strains were targeted for immunization. Human properdin was used as the immunogen and several IgG2 and IgG4 XenoMouse animals received either footpad or tail-vein immunizations. Fusions with splenocytes from both IgG2 and IgG4 animals were performed, and IgG2 hybridoma supernatant samples were determined to bind to human properdin. These samples were evaluated for their ability to neutralize properdin function. The results reveal that several of the fully human anti-properdin MoAbs block properdin function.

MATERIALS AND METHODS

Generation of Hybridomas

[00165] Xenomouse animals were immunized via footpad route for all injections. Total volume of each injection was 50 μl per mouse, or 25 μl per footpad Initial injections were with 10 μg human properdin in pyrogen free DPBS, admixed 1:1 v/v with TiterMax Gold per mouse. Subsequent boosts were made with 10ug Human Properdin in pyrogen free DPBS admixed with 25 μg of Adju-Phos (aluminum phosphate gel) per mouse for six times, then a final boost of 10 μg human properdin in pyrogen free DPBS without adjuvant per mouse. The animals were immunized on days 0, 3, 6, 10, 13, 17, 20, and 24 for this protocol; and fusions were performed on day 29. Following the immunization regimen described above, mice were euthanized, then inguinal and lumbar lymph nodes were recovered.

[00166] Lymphocytes were released by mechanical disruption of the lymph nodes using a tissue grinder, followed by depletion of T cells by CD90 negative selection. The fusion was performed by mixing washed enriched B cells and nonsecretory myeloma P3X63Ag8.653 cells purchased from ATCC, cat. # CRL 1580 (Kearney et al, J. Immunol. 123, 1979, 1548-1550) at a ratio of 1:1. The cell mixture was gently pelleted by centrifugation at 800g. After complete removal of the supernatant, the cells were treated with 2-4 mL of Pronase solution (CalBiochem, cat. # 53702; 0.5 mg/ml in phosphate buffered saline (PBS)) for no more than 2 minutes. Then 3-5 ml of fetal bovine serum (FBS) was added to stop the enzyme activity and the suspension was adjusted to 40 ml total volume using electro-cell fusion solution, ECFS (0.3M Sucrose, Sigma, Cat# S7903, 0.1mM Magnesium Acetate, Sigma, Cat# M2545, 0.1mM Calcium Acetate, Sigma, Cat# C4705). The supernatant was removed after centrifugation and the cells were resuspended in 40 ml ECFS. This wash step was repeated and the cells again were resuspended in ECFS to a concentration of 2×10^6 cells/ml. Electro-cell fusion was performed using a fusion generator (model ECM2001, Genetronic, Inc., San Diego, CA.). The fusion chamber size used was 2.0 ml using the following instrument settings.

[00167] Alignment condition: voltage: 50 v, time: 50 s

- [00168] Membrane breaking at: voltage: 3000 v, time: 30 μ s
- [00169] Post-fusion holding time: 3 s
- [00170] After fusion, the cells were resuspended in hybridoma fusion medium: DMEM (JRH Biosciences), 15% FBS (Hyclone), containing 0.5 x Azaserine hypoxanthine (HA) (Sigma, cat. # A9666), and supplemented with L-glutamine, pen/strep, OPI (oxaloacetate, pyruvate, bovine insulin) (all from Sigma) and IL-6 (Boehringer Mannheim) for culture at 37 °C, and 10% CO₂ in air. Cells were plated in flat bottomed 96-well tissue culture plates at 4x10⁴ cells per well. Cultures were maintained in hybridoma fusion medium for 2 weeks before transfer to Hybridoma medium: DMEM (JRH Biosciences), 15% FBS (Hyclone), and supplemented with L-glutamine, pen/strep (penicillin/streptomycin), OPI (oxaloacetate, pyruvate, bovine insulin) (all from Sigma) and IL-6 (Boehringer Mannheim). Hybridomas were selected for by survival in 0.5x HA hybridoma fusion medium and supernatants from those wells containing hybridomas were screened for antigen reactivity by enzyme-linked immunosorbent assay (ELISA).

- [00171] Cloning was performed on selected antigen-positive wells using limited dilution plating. Plates were visually inspected for the presence of single colony growth and supernatants from single colony wells were then screened by antigen-specific ELISAs as described above. Highly reactive clones were assayed to verify purity of human gamma and kappa chain by multiplex ELISA using a Luminex instrument.

Enzyme-linked immunosorbent assay (ELISA)

- [00172] The ELISA format entailed incubating supernatants on antigen coated plates (human properdin coated plates) and detecting human anti-human properdin binding antibodies using horseradish peroxidase (HRP) labeled mouse anti-human IgG. All positive samples were confirmed by two sets of ELISA in parallel, which entailed incubating supernatants on antigen coated plates (human properdin coated plates) and detecting human anti- human properdin binding antibodies using horseradish peroxidase (HRP) labeled mouse anti-human Gamma and Kappa chain.

LPS Complement Activation – C5b-9 Assay

- [00173] Complement within human serum is activated by lipopolysaccharide (LPS) that has been immobilized onto microtiter wells. This results in the covalent attachment of C5b-9 to the LPS. Briefly, microtiter wells (medium binding plates, Corning Costar) were coated with 1 μ g/50 μ l/well of LPS from *Salmonella typhosa* (Sigma Chemical) in 50 mM sodium bicarbonate buffer pH 9.5 overnight at 4°C. After aspirating the LPS solution, wells were blocked with 1% BSA in PBS for 2 hours at room temperature. At the end of this incubation,

wells were washed with PBS and incubated with 8% normal human serum in either a) 0.4% HSA (human serum albumin) in Mg⁺⁺-EGTA-VBS buffer (5 mM diethyl barbiturate, 120 mM NaCl, 5 mM MgCl₂, 5 mM EGTA, pH 7.2) or b) 0.4% HSA in EDTA-VBS buffer (5 mM diethyl barbiturate, 120 mM NaCl, 20 mM EDTA). Samples in EDTA-VBS served as background controls.

[00174] The microtiter plates were incubated at 37°C for 1 hour in a water bath to allow LPS-mediated complement activation to occur. The plates were washed with PBS and the deposited C5b-9 was detected by adding a mouse anti-human C5b-9 monoclonal antibody (Quidel Corp, San Diego, CA) at 1:1000 dilution in 1% blocking solution. Following a 1 hour incubation at room temperature, the plates were washed again with PBS and a peroxidase-conjugated goat anti-mouse antibody (Sigma, 1:2000 dilution in blocking solution) was added. Following a 1 hour incubation at room temperature the plates were rinsed extensively with PBS, and 100 µl of 3,3', 5,5' tetramethyl benzidine (TMB) substrate (Kirkegaard & Perry Laboratories) was added. The reaction of TMB was quenched by the addition of 100 µl of 1 M phosphoric acid, and plates were read at 450 nm in an ELISA plate reader.

[00175] The effect of IgG2 samples on C5b-9 formation was evaluated by adding 3 µg/ml of IgG to a fixed concentration of human serum. The extent of inhibition of C5b-9 formation was determined using the antibody detection system described above.

C3b-Properdin Binding Assay

[00176] Polystyrene microtiter plates (96-well medium binding plates, Corning Costar) were coated with human C3b (0.5 µg/50 µl/well; Calbiochem, San Diego, CA) in PBS overnight at 4°C. After aspirating the C3b solution, wells were blocked with PBS containing 1% BSA for 2 hours at room temperature. Wells without C3b coating served as background controls. The ability of IgG2 samples to inhibit C3b-properdin binding was evaluated by adding various IgG2 samples (final concentration 3 µg/ml) to a constant concentration of properdin (1 nM). Following a 2 hour incubation at room temperature, the wells were extensively rinsed with PBS. C3b-bound properdin was detected by the addition of mouse anti-human properdin monoclonal antibody P#2 (Quidel, San Diego, CA) at 1:1000 dilution in blocking solution, which was allowed to incubate for 1 hour at room temperature. After washing plates with PBS, peroxidase-conjugated goat anti-mouse antibody (1:1000 dilution in blocking solution) was added and allowed to incubate for 1 hour. The plates were again rinsed thoroughly with PBS, and 100 µl of TMB substrate was added. The reaction of TMB was quenched by the addition of 100 µl of 1 M phosphoric acid and the plates were read at 450 nm in a microplate reader.

LPS Complement Activation - C3c Assay

[00177] Complement within human serum is activated by lipopolysaccharide (LPS) that has been immobilized onto microtiter wells. This results in the covalent attachment of C3c to the LPS. Briefly, polystyrene microtiter plates (medium binding plates, Corning Costar) were coated with LPS from *Salmonella typhosa* (1 µg/50 µl/well, Sigma Chemical Co) in 50 mM bicarbonate buffer, pH 9.5 overnight at 4°C. After aspirating the LPS solution, wells were blocked with PBS containing 1% BSA for 1 hr at room temperature and then washed with PBS and placed on ice. Samples containing IgG (1 µg/ml) and 8% normal human serum in either Mg⁺⁺-EGTA-GVB buffer (13 mM MgCl₂, 13 mM EGTA in gelatin veronal buffer, pH 7.3) or EDTA-GVB buffer (20 mM EDTA in gelatin veronal buffer, pH 7.3) were prepared at 4°C and samples (50 µl/well) transferred to the microtiter plates.

[00178] Complement was activated by heating the microtiter plates at 37°C for 30 min. The plates were then cooled to 0°C in a water bath to stop further complement activation and washed extensively with cold PBS-Tween (0.05% Tween 20™ non-ionic detergent in PBS). Rabbit anti-human C3c (DAKO #A0062, 1:10,000 dilution) in PBS-bovine serum albumin (BSA) (PBS containing 2 mg/ml BSA) was added and allowed to incubate for 1 hr at room temperature. After washing the plate with PBS, peroxidase-conjugated goat anti-rabbit antibody (American Qualex, 1:10,000 dilution) in PBS-BSA was added and allowed to incubate for 1 hour at room temperature. The plate was again rinsed thoroughly with PBS, and 100 µl of TMB substrate was added. The reaction of TMB was quenched by the addition of 100 µl of 1 M phosphoric acid, and the plate was read at 450 nm in a microplate reader.

RESULTS

[00179] Eleven samples were analyzed for their ability to 1) inhibit lipopolysaccharide (LPS)-induced activation of the complement alternative pathway and 2) to block properdin binding to the complement protein, C3b. The samples are designated 1.1, 1.2, 1.6, 1.7, 1.11, 1.14, 1.16, 1.20, 1.21, 1.22, and 1.25 in Figures 1, 2, and 3. Monoclonal antibody #23 (MoAb #23) was included as a positive control.

[00180] Several of the IgG2 supernatant samples caused a reduction in the formation of the complement activation product, C5b-9, when tested at 3 µg/ml in the LPS-activated alternative pathway assay (Fig. 1). In particular, samples 1.1, 1.6, 1.11, 1.16, and 1.22 caused ≥50% inhibition of C5b-9 formation. The activities of samples 1.11 and 1.16 approached the level of inhibition observed with MoAb #23, a potent blocking murine anti-human properdin IgG1 that was included as a positive control in the assay.

[00181] Analysis of the supernatant samples in the C3b-properdin binding assay revealed a general concordance with the results of the LPS-activation assay. In particular, samples 1.6, 1.11 and 1.22 caused 50% or more inhibition of properdin binding to C3b (Fig. 2). Interestingly, samples 1.1 and 1.16, which were active in the LPS-activation assay, showed little activity in the C3b-properdin binding assay. This suggests that these samples may block complement alternative pathway function without disrupting properdin binding to C3b. The samples containing low concentrations of IgG2 were also tested in this assay at the highest concentrations practicable. The results of this analysis, which are summarized in Table 1, indicate that sample 1.12 was an effective inhibitor of C3b-properdin binding, since 0.25 µg/ml caused a significant effect. Given the relatively low concentration that was tested, it also appears that sample 1.13 has appreciable blocking activity.

Table 1. Analysis of Dilute IgG2 Samples in a C3b-Properdin Binding Assay

Sample #	µg/ml	% Bound	SD
1.3	0.27	92.1	0.5
1.8	0.12	95.9	4.6
1.12	0.25	23.1	4.7
1.13	0.43	58.9	2.5
1.17	0.57	81.4	3.0
1.19	0.80	64.4	1.9
1.24	1.40	87.1	2.2

[00182] A second complement alternative pathway assay was utilized to confirm that sample 1.1 and 1.16 could inhibit complement activation, even though they did not block C3b-properdin binding. This assay also relies on LPS activation of complement, but measures the formation of the activation product, C3c, instead of C5b-9. It should be noted that this assay was run with 1 µg/ml of the samples instead of the 3 µg/ml used in the previous examples. In agreement with the results presented in Fig. 1, the most active samples in the C3c assay were 1.11 and 1.16 (Fig. 3). In addition, sample 1.6 appeared to partially inhibit alternative pathway activation. None of the samples were as active as the standard anti-properdin MoAb #23. However, since these samples are likely to be mixtures of clones, there may be multiple IgG2 species in each sample supernatant. The observation that sample 1.16 was active in two separate functional assays, but inactive in the C3b-properdin binding assay, appears to confirm that this MoAb is acting by a unique mechanism.

[00183] The aforementioned lines exhibiting activity in the above assays were cloned and further evaluated to confirm their potency in inhibiting complement activation. More specifically, lines 1.16, 1.11, 1.22, and 1.6 were cloned and re-evaluated. Clones of the 1.16,

1.22, and 1.11 lines were determined to be only partial inhibitors of C3c generation. Based on those results, no further studies were performed on clones derived from lines 1.16, 1.22, and 1.11. However, clones of the 1.6 line were determined to be potent inhibitors of C3c generation. The lead candidate clone from the 1.6 line is designated as 1.6.2.1.3 and was further analyzed to determine its efficacy in inhibiting complement activation.

Example 2: Anti-properdin monoclonal antibodies inhibit C3c and sC5b-9 generation in 8% human serum

MATERIALS AND METHODS

Human C3c and sMAC ELISA Assay

[00184] Sigma *S. typhosa* LPS L6386 (25 mg/sample) was used. LPS (3 mg) was dissolved in 1 ml of carbonate buffer, and diluted to 20 µg/ml in carbonate buffer (1:150 dilution). LPS stock solution was made fresh before use. Wells were coated overnight at 4°C with 50 µl/well of 20 µg/ml LPS in 50mM carbonate buffer pH 9.5 (1 µg LPS/well).

[00185] Carbonate buffer was made by dissolving 0.265g of Na₂CO₃ in 50 ml sterile H₂O for 50mM stock solution. AP Buffer (13 mM EGTA, 13mM MgCl₂ in Gelatin Veronal Buffer (Sigma-Aldrich, Catalog number: G6514) pH 7.3) was made. As a negative control, 13 mM EDTA in Gelatin Veronal Buffer was used. Human serum (QED BioScience, Inc.) was prepared by diluting human serum to 16% with AP buffer, or with EDTA-Gelatin Veronal Buffer. Antibody samples were diluted to a concentration of 180 µg/ml in 2 mg/ml BSA-PBS and labeled as STOCK A. Stocks B, C, and D were made by preparing serial 1:10 dilutions of Stock A in 2 mg/ml BSA-PBS.

[00186] ELISA assays were carried out as follows. Wells of a 96-well microtiter plate were coated with 1 µg of freshly-prepared LPS in a volume of 50 µl per well. Plates were incubated overnight at 4°C. Wells were washed 3 times with 200 µl PBS. 100 µl Blocking Buffer (30 ml PBS, 300 mg BSA, i.e. 1% BSA) were added; and plates were incubated for 1 hour at room temperature. Wells were washed 3 times using 200 µl PBS. The plates were subsequently kept on ice, and 50 µl sample added per well (in quadruplicate). The plates were incubated for 30 minutes at 37°C in a water bath. The reaction was stopped by transferring the plate from water bath to ice bucket with ice-water mix. The supernatant sample was harvested into a 0.7 ml tube on ice for subsequent C3a and sC5b-9 ELISA assays. Sample were stored at -70°C.

[00187] Wells were washed 3 times using 200 µl of ice cold PBS-Tween 20 (0.05% Tween 20 in PBS- 250 µl Tween 20 in 500 ml PBS). Washes were performed on ice. Wells were washed

twice with 200 μ l PBS at room temperature. 100 μ l/well of a 1:10,000 dilution of DAKO A0062 rabbit anti-human C3c (primary Ab) in PBS-BSA (2 mg/ml) was added. Plates were incubated for 1 hour at room temperature. Wells were washed 5 times with 200 μ l PBS. 100 μ l of a 1:10,000 dilution of American Qualex (A102PU) peroxidase conjugated goat anti-rabbit IgG (secondary antibody) in PBS- 2mg/ml BSA was added. A solution containing 2.2 μ l of antibody was prepared. Plates were incubated for 1 hour at room temperature. Following the incubation, plates were washed 5 times with 200 μ l PBS. Substrate pre-warmed to room temperature was added (100 μ l/well), and plates were incubated for approximately 5 minutes (at room temperature). The reaction was stopped with 100 μ l 1N H₃PO₄ and OD₄₅₀ measured.

RESULTS

[00188] The results are shown in Figures 4 and 5. Figure 4 demonstrates a dose-dependent inhibition of sMAC production in an *in vitro* LPS assay using anti-properdin antibodies. As shown above, using an isotype PK control antibody, no inhibition of sMAC production is observed. A fully intact anti-properdin (clone 1.6.2.1.3) or F(ab)'₂ antibody exhibited near complete inhibition of sMAC production at a concentration of 10 μ g/ml. Figure 5 demonstrates a dose-dependent inhibition of C3a production in an *in vitro* LPS assay using anti-properdin antibodies. As shown above, using an isotype PK control antibody, no inhibition of sMAC production is observed. A fully intact anti-properdin (clone 1.6.2.1.3) or F(ab)'₂ antibody exhibited significant inhibition of C3a production at a concentration of 10 μ g/ml.

Example 3: The effects of anti-properdin monoclonal antibodies on inhibition of complement activation in a tubing loop model of cardiopulmonary bypass

Experimental Design

[00189] In this experiment, tubing loops were filled with 1.5 ml of diluted blood from a healthy volunteer. The tubing loops were rotated vertically in a water bath at 37°C for 2 hours to allow for complement activation to occur. Blood samples from the tubing loops were transferred into polypropylene tubes that were pre-loaded with EDTA for determining complement activation. The addition of EDTA prevents further complement activation that would otherwise occur during sample processing. Blood samples were centrifuged to separate plasma and aliquoted for analysis.

Materials/Reagents

[00190] Blood (25 ml) was collected in a 50-ml polypropylene tube containing 125 μ l of porcine heparin. Blood was diluted 1:1 with plasmalyte-148 (Baxter Healthcare Corporation) for a final heparin concentration of 2.5 units per ml of diluted blood. To each tube was added

700 µl PBS (untreated), intact antibody, or F(ab)[']₂ antibody (final concentration of 200 µg/ml or 133 µg/ml respectively). As a negative control, 1.5 ml of diluted blood was added to a polypropylene tube containing 48 µl of EDTA (20mM final concentration). The negative control sample was not be added to the tubing loop and represented a background control.

[00191] The polyethylene tubing (16.5 inches) was filled with 1.5 ml of blood sample and closed into a loop with a piece of silicone tubing. The tubing was incubated in a water bath at 37°C, and rotated vertically. Following the 2 hour incubation at 37°C, the blood samples were aliquoted into polypropylene tubes (4.0 ml capacity) preloaded with 0.5M EDTA (final EDTA concentration of 20mM). The blood samples were centrifuged at 4°C (2,500G for 20 minutes) to collect the plasma. C3a, sMAC, and C5a levels were evaluated by ELISA.

RESULTS

[00192] The results are shown in Figures 6, 7, and 8. Figure 6 illustrates the production of sMAC levels in the tubing loop model using blood diluted 1:1 in plasmalyte-148. This study demonstrates that sMAC levels increase rapidly and peak at 2 hours. Figure 7 illustrates the production of C3a levels in the tubing loop model using blood diluted 1:1 in plasmalyte-148. This study demonstrates that C3a levels increase rapidly and peak at 3 hours. Figure 8 demonstrates that anti-properdin antibodies effectively inhibit C3a production in the tubing loop model in a dose dependent manner. In the above study, a fully intact (clone 1.6.2.1.3), a F(ab)[']₂, and a Fab anti-properdin antibody was evaluated. All of the aforementioned antibodies provided near complete inhibition of C3a production at a concentration of 10 µg/ml of blood.

Example 4: The effects of anti-properdin monoclonal antibodies on complement in blood exposed to extracorporeal circulation

Experimental Design

[00193] A fully-human anti-properdin monoclonal F(ab')₂ antibody fragment was generated to evaluate its ability to inhibit complement activation in a CPB model. More specifically, the study shown below was designed to evaluate the effects of the anti-properdin F(ab')₂ antibody on the activation of complement in blood exposed to extracorporeal circulation via the use of pediatric cardiopulmonary bypass (CPB) units. Briefly, pediatric bypass circuits were assembled in a fashion that is consistent with their use during clinical practice. Two circuits were run simultaneously with freshly collected heparin-treated human blood, using a common roller pump, oxygenator and temperature regulator. The blood in one of the parallel circuits was treated with the F(ab')₂ anti-properdin antibody, whereas the blood in the other circuit was treated with an isotype-matched antibody. At regular intervals during the simulated CPB

procedure, blood samples were collected to allow for the measurement of complement activation products.

Test Method

[00194] (1) Extracorporeal circuits were assembled using a hollow-fiber pediatric membrane oxygenator with an integrated heat exchanger module (D 901 Lilliput 1; Dideco, Mirandola, Italy), a pediatric venous reservoir with an integrated cardiotomy filter (D754 Venomicard; Dideco), a perfusion tubing set (Sorin Biomedical, Inc., Irvine, CA) and a multiflow roller pump. To allow precise comparison of the effect of addition of test and control antibody to blood, each experiment consisted of simultaneously running both blood samples in parallel extracorporeal circuits using the same multiflow roller pump.

[00195] (2) On the day of the experiment, fresh whole human blood (2 volumes of ~225 mL each) were drawn into transfer packs containing porcine heparin (1125 units). Prior to participation, volunteers were required to meet the following entrance criteria:

[00196] **Inclusion Criteria:**

[00197] 1. Males

[00198] 2. Rated Class 1 (normal, healthy) under the American Society of Anesthesiologists (ASA) guidelines

[00199] 3. Between the ages of 18 and 65 years old

[00200] 4. Weigh at least 110 pounds

[00201] **Exclusion Criteria:**

[00202] 1. Donated blood in the past eight weeks

[00203] 2. Currently taking drugs that could inhibit platelet aggregation

[00204] 3. Pre-draw abnormal blood pressure, pulse rate, temperature, or hematocrit

[00205] (3). The anti-properdin F(ab')₂ antibody or isotype-matched antibody control agent were added to the transfer packs following collection. Transfer packs were weighed in order to determine the exact amount of blood used in each circuit. The total amount of heparin used should be 5 units per mL of blood

[00206] (4). Prior to the addition of blood to the extracorporeal circuit, two 1.5-mL samples of blood were removed from the transfer pack and mixed with an equal volume of plasmalyte-148. This diluted blood sample is treated as described in step 7 below. This sample represents t = 0 min.

[00207] (5). The CPB circuits were primed with 450 mL of plasmalyte-148 at 32°C and circulated at 500 mL/min while the sweep gas flow was maintained at 0.25 liters per min using 100% oxygen. The sweep gas was changed to a mixture of oxygen (95%) and carbon dioxide

(5%) after the blood was added to the circuit. Once the system was primed, 200 mL of blood was added to the reservoir via the prime port. Following the addition of the blood, 250-mL of prime fluid (plasmalyte-148) was simultaneously withdrawn distal to the oxygenator outlet to yield a final circuit volume of 400 mL. The pH, pCO₂, pO₂ and perfusate temperature were continuously recorded throughout the recirculation period. Blood was circulated with the prime fluid to allow complete mixing for 3-min. After the 3 minutes, a 3-mL aliquot of circulated blood:plasmalyte-148 (1:1) was collected from the circuit (t = 3 min). (Note, the final heparin concentration, after dilution with the prime fluid is 2.5 units of heparin/mL of diluted blood).

[00208] (6). To mimic the procedures of surgical operation under hypothermia, the following protocol is followed for cooling and re-warming of blood. Following the mixing of the blood and plasmalyte-148, the blood was: a) cooled to 27°C over a 5 min period; b) circulated through the CPB circuit for 60 min; c) rewarmed to 37°C over a 30 min period.

[00209] (7). Two 1.5-mL blood samples were collected at various time intervals from each CPB circuit (3, 8, 15, 30, 40, 50, 60, 68, 80, 90, and 98 minutes, as well as a terminal sample). The timetable shown in Table 2 was observed:

Table 2

Time	Event
Pre-run	Prime circuits with 200 mL plasmalyte-148 Draw Blood Collect samples
0 min	Add 200 mL blood to circuit Run circuit for 3 min to mix
3 min	Collect samples Initiate cooling to 27°C for 5 min
8 min	Collect samples Run circuit for 60 min
15 min	Collect samples
30 min	Collect samples
40 min	Collect samples
50 min	Collect samples
60 min	Collect samples
68 min	Collect samples Initiate warming to 37°C for 30 min
80 min	Collect samples
90 min	Collect samples
98 min	Collect samples Terminate circulation

[00210] (8). Immediately upon collection of the blood samples, the two samples were individually centrifuged at 2000 x g at 4°C to separate the plasma.

[00211] (9). The resultant plasma samples were frozen on dry ice and stored at -80°C for subsequent analysis in the complement activation assays.

RESULTS

[00212] The results are shown in Figures 9 and 10.

[00213] Figure 9 illustrates the effects of anti-properdin antibodies in an *ex vivo* CPB model. More specifically, a fully intact (clone 1.6.2.1.3), a F(ab)₂, and Fab anti-properdin antibody was evaluated at various concentrations to determine efficacy in inhibiting complement activation. These results represent the average C3a values from several individuals for each respective cohort as indicated in the figure. The standard deviations are represented as vertical bars. A pronounced activation of complement is evident in the above study as measured by C3a levels in the control samples. A significant inhibition of C3a levels was observed when a fully intact anti-properdin antibody was used (dosage of 200 µg/ml of blood), as well as when a molar equivalent dose of F(ab)₂ at 133 µg/ml of blood was evaluated. It is also important to note that an equivalent level of inhibition was observed with the F(ab)₂ antibody at a dose of 25 µg/ml. Lastly, this study also demonstrates that an anti-properdin Fab antibody effectively inhibited C3a production in the above model. Surprisingly, the Fab antibody demonstrated efficacy at a dosage as low as 3 µg/ml of blood.

[00214] Figure 10 illustrates the effects of anti-properdin antibodies in an *ex-vivo* CPB model. More specifically, a fully intact (clone 1.6.2.1.3), a F(ab)₂, and Fab anti-properdin antibody was evaluated at various concentrations to determine efficacy in inhibiting complement activation. These results represent the average C3a values from several individuals for each respective cohort as indicated in the figure. The standard deviations are represented as vertical bars. A pronounced activation of complement is evident in the above study as measured by sMAC levels in the control samples. A significant inhibition of sMAC levels was observed when a fully intact anti-properdin antibody was used (dosage of 200 µg/ml of blood), as well as when a molar equivalent dose of F(ab)₂ at 133 µg/ml of blood was evaluated. These results are consistent with the findings observed measuring C3a levels. It is also important to note that an equivalent level of inhibition was observed with the F(ab)₂ antibody at a dose of 25 µg/ml. Lastly, this study also demonstrates that an anti-properdin Fab antibody effectively inhibited sMAC production in the above model. Surprisingly, the Fab antibody demonstrated efficacy at a dosage as low as 3 µg/ml of blood.

[00215] High resolution Biacore analysis was conducted on anti-properdin antibodies using human properdin. Affinity measurements were recorded for intact, Fab, and F(ab)₂ anti-properdin antibodies. The data are presented in Table 3, below.

Table 3

25°C	ka (M ⁻¹ s ⁻¹)			kd (s ⁻¹)			Kd (pM)		
	AVG	SD	95% C.I.	AVG	SD	95% C.I.	AVG	SD	95% C.I.
Intact Ab	3.40E+04	20489.3	50868.21	9.75E-07	1.01E-06	2.515E-06	41.33	56.92	141.32
Fab	5.64E+04	17902.82	44445.68	9.73E-08	4.20E-08	1.043E-07	1.67	0.208	0.517
F(ab)₂	5.29E+04	7526.772	18686.02	8.23E-07	2.80E-07	6.953E-07	15.83	7.42	18.43

[00216] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

CLAIMS

What is claimed is:

1. An isolated human antibody that specifically binds properdin.
2. The antibody of claim 1, wherein said antibody is a monoclonal antibody.
3. The antibody of claim 1, wherein said antibody comprises a light chain comprising a complementarity determining region (CDR) comprising an amino acid sequence chosen from SEQ ID NO:31, SEQ ID NO:36, and SEQ ID NO:41.
4. The antibody of claim 1, wherein said antibody comprises a heavy chain comprising a complementarity determining region (CDR) comprising an amino acid sequence chosen from SEQ ID NO:59, SEQ ID NO:64, and SEQ ID NO:69.
5. The antibody of claim 1, wherein said antibody comprises a light chain comprising a complementarity determining region (CDR) 1 comprising SEQ ID NO:31, a CDR2 comprising SEQ ID NO:36, and a CDR3 comprising SEQ ID NO:41; and wherein said antibody comprises a heavy chain comprising a CDR1 comprising SEQ ID NO:59, a CDR2 comprising SEQ ID NO:64, and a CDR3 comprising SEQ ID NO:69.
6. The antibody of claim 1, wherein said antibody comprises a light chain comprising an amino acid sequence having at least about 85% amino acid sequence identity to SEQ ID NO:14; and a heavy chain comprising an amino acid sequence having at least about 85% amino acid sequence identity to SEQ ID NO:16.
7. The antibody of claim 1, wherein said antibody is selected from a single chain antibody, a Fab fragment, and a F(ab')₂ fragment .
8. The antibody of claim 1, wherein the antibody specifically binds an epitope within a thrombospondin type 1 repeat of properdin.
9. The antibody of claim 1, wherein said properdin is human properdin.

10. The antibody of claim 1, wherein said antibody inhibits binding of properdin to complement component C3b.
11. A composition comprising the antibody of claim 1.
12. The composition of claim 11, wherein said composition comprises a pharmaceutically acceptable excipient.
13. An isolated polynucleotide comprising a nucleotide sequence that encodes an antibody of claim 1.
14. An expression vector comprising the polynucleotide of claim 13.
15. An isolated host cell that comprises a polynucleotide of claim 13.
16. An isolated host cell that comprises an expression vector of claim 14.
17. A method of inhibiting activation of the alternative complement pathway in a mammalian host, the method comprising administering to said host an effective amount of an antibody of claim 1.
18. The method of claim 17, wherein the level of one or more of C3c, membrane attack complex, and anaphylatoxin is reduced.
19. The method of claim 18, wherein the anaphylatoxin is selected from C3a and C5a.
20. A method of treating an alternative complement pathway-mediated disorder in a mammalian host, the method comprising administering to the host an effective amount of an antibody of claim 1.
21. The method of claim 20, further comprising administering a second anti-inflammatory agent.

22. The method of claim 20, wherein the alternative complement pathway-mediated disorder is selected from inflammation, acute respiratory distress syndrome, post-cardiopulmonary bypass inflammation, septic shock, transplant rejection, burn injury, systemic lupus erythematosus, membranous nephritis, pemphigoid, dermatomyositis, and anti-phospholipid syndrome.

1 / 24




FIG. 1

2 / 24




FIG. 2

3 / 24





FIG. 3


4 / 24

FIG. 4



5 / 24

FIG. 5



6 / 24

Production of sMAC in Tubing Loop Model




FIG. 6

7 / 24





FIG. 7


8 / 24

FIG. 8




9 / 24

FIG. 9




10 / 24

FIG. 10



11 / 24

FIG. 11



12 / 24

Ab No	Chain Name	V	J	FR1
GL				DIQMTQSPSSLSASVGDRVTITC
1	GL001H1 12 1 1N1K	A20	JK1	-----
2	GL001H1 6 2 1N1K	"	"	-----S--
GL				DIQMTQSPSSLSASVGDRVTITC
3	GL001H8 14 1N1K	O12	JK4	-----
GL				DIQMTQSPSSVSASVGDRVTITC
4	GL001H8 7 1N1K	L5	JK1	-----
GL				DIQMTQSPSSLSASVGDRVTITC
5	GL001H8 11 1N1K	O18	JK4	-----

Ab No	CDR1	FR2	CDR2
GL	RASQGISNYLA	WYQQKPGKVPKLLIY	AASTLQS
1	-----	-----	-----
2	----D-----	-----	-----
GL	RASQSISSYLN	WYQQKPGKAPKLLIY	AASSLQS
3	----N---F--	----S-----F	-T-R---
GL	RASQGISSWLA	WYQQKPGKAPKLLIY	AASSLQS
4	-----	-----	V-----
GL	QASQDISNYLN	WYQQKPGKAPKLLIY	DASNLET
5	-----	-----	---T---

Ab No	FR3	CDR3	J	SEQ ID NO
GL	GVPSRFGSGSGTDFTLTISSLQPEDVATYYC	QKYNAPWT	FGQGTKVEIKR	21
1	-----	---D---	-----	22
2	-----	-----	-----	23
GL	GVPSRFGSGSGTDFTLTISSLQPEDFATYYC	QQSYS###T	FGGGTKVEIKR	24
3	----I-----G-----F--	----IPL-	-----D---	25
GL	GVPSRFGSGSGTDFTLTISSLQPEDFATYYC	QQANSF##T	FGQGTKVEIKR	26
4	-----I-----	---D--PR-	-----	27
GL	GVPSRFGSGSGTDFTFTISSLQPEDVATYYC	QQYDNLPLT	FGGGTKVEIKR	28
5	-----	-N-----	-----	29

FIG. 12

Ab No	Clone	VL	V Sequence	#N's	N	JL
1	GL001H1 12 1 INIK	A20 (1-284)	TGCCCC	0		JK1 (285-322)
2	GL001H1 6 2 INIK	A20 (1-284)	TGCCCC	0		JK1 (285-322)
3	GL001H8 14 INIK	O12 (1-280)	ACAGTA	6	TTCCAC	JK4 (287-322)
4	GL001H8 11 INIK	O18 (46-331)	TCCCTC	0		JK4 (332-367)
5	GL001H8 7 INIK	L5 (1-284)	TTTCCC	2	CC	JK1 (287-322)

Ab No	J Sequence	Constant Region	CDR1	CDR2	CDR3	CDR1 AA Seq
1	GTGGAC	IGKC (323-642)	70-102	148-168	265-291	RASQGISNYLA (SEQ ID NO:30)
2	GTGGAC	IGKC (323-642)	70-102	148-168	265-291	RASQDISNYLA (SEQ ID NO:31)
3	TCACTT	IGKC (323-462)	70-102	148-168	265-291	RASQNISSFLN (SEQ ID NO:32)
4	TCACTT	IGKC (368-514)	115-147	193-213	310-336	QASQDISNYLN (SEQ ID NO:33)
5	GGACGT	IGKC (323-462)	70-102	148-168	265-291	RASQGISSWLA (SEQ ID NO:34)

Ab No	CDR2 AA Seq	CDR3 AA Seq
1	AASTLQS (SEQ ID NO:35)	QKYDSAPWT (SEQ ID NO:40)
2	AASTLQS (SEQ ID NO:36)	QKYNAPWT (SEQ ID NO:41)
3	ATSLRQS (SEQ ID NO:37)	QQSYSLPLT (SEQ ID NO:42)
4	DASTLET (SEQ ID NO:38)	QNYDNLPLT (SEQ ID NO:43)
5	VASSLQS (SEQ ID NO:39)	QQADSFPRT (SEQ ID NO:44)

FIG. 13

14 / 24
FIG. 14

	Chain Name	V	D
GL			
3	GL001H8 14 1N1G4	VH3-33	D3-22
GL			
4	GL001H8 11 1N1G2	VH3-33	D3-16
GL			
2	GL001H1 6 2 1N1G2	VH1-24	D3-9
GL			
5	GL001H8 7 1N1G4	VH4-31	D7-27
GL			
1	GL001H1 12 1 1N1G2	VH4-59	D1-7

Ab No	J	FR1	CDR1
GL		QVQLVESGGGVVQPGRSLRLSCAAS	GFTFSSYGMH
3	JH6B	###QE-----	-----N--I-
GL		QVQLVESGGGVVQPGRSLRLSCAAS	GFTFSSYGMH
4	JH6B	-----	-----C----
GL		QVQLVQSGAEVKKPGASVKVSCKVS	GYTLTELSMH
2	JH6B	-----	-----
GL		QVQLQESGPGLVKPSQTLSTCTVS	GGSISSGGYYWS
5	JH4B	----EQ-----	-D-----H---
GL		QVQLQESGPGLVKPSQTLSTCTVS	GGSISSYYWS
1	JH3B	-----	-----I-----

Ab No	FR2	CDR2	FR3
GL	WVRQAPGKGLEWVA	VIWYDGSNKYYADSVKG	RFTISRDNKNTLYLQMNLSRAEDTAVYYCAR
3	-----	-----N-----	-----
GL	WVRQAPGKGLEWVA	VIWYDGSNKYYADSVKG	RFTISRDNKNTLYLQMNLSRAEDTAVYYC#G
4	-----	-----	-----A-
GL	WVRQAPGKGLEWVG	GFDPEDGETIYAQKFG	RVTMTEDTSTDYAMELSSLRSEDVAVYYCA#
2	-----	-----M---	-----D-----T
GL	WIRQHPGKGLEWIG	YIYYSGSTYYNPSLKS	RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR
5	-----	-----S-----	-F-----T-----
GL	WIRQPPGKGLEWIG	YIYYSGSTNYNPSLKS	RVTISVDTSKNQFSLKLSSVTAADTAVYYCA#
1	-----	-----	-----V

Ab No	CDR3	J	SEQ ID NO:
GL	##YYDSSGYY##YYYYGMDV	WGQGTIVTVSSA	45
3	GG-----R---TP-----	-----	46
GL	G###MDV	WGQGTIVTVSSA	47
4	-ATA---	-----	48
GL	##YYDILTG##YYYYGMDV	WGQGTIVTVSSA	49
2	GT-----PS-----LG-	-----	50
GL	TGDYFDY	WGQGTIVTVSSA	51
5	-----	←L-----	52
GL	WNY##AFDI	WGQGTIVTVSSA	53
1	---GD---	-----	54

15 / 24

Ab No	Clone	VH	V Sequence	#N's	N
3	GL001H8 14 1N1G4	VH3-33 (1-286)	CGAGAG	4	GGGG
4	GL001H8 11 1N1G2	VH3-33 (61-350)	CTGTGC	1	C
2	GL001H1 6 2 1N1G2	VH1-24 (1-293)	TGCAAC	6	CGGAAC
5	GL001H8 7 1N1G4	VH4-31 (1-297)	GCGAGA	0	
1	GL001H1 12 1 1N1G2	VH4-59 (1-288)	TGTGCG	3	GTT

Ab No	D1	D1 Sequence	#N's	N	D2	D2 Sequence
3	D3-22 (291-315)	TTACTATGATAGTCGTGGTTATTAC (SEQ ID NO:55)	-N.A-	-N.A-	-N.A-	-N.A-
4	D3-16 (352-358)	GGGGGAG	-N.A-	-N.A-	-N.A-	-N.A-
2	D3-9 (300-321)	GTATTACGATATTTGACTGGT (SEQ ID NO:56)	-N.A-	-N.A-	-N.A-	-N.A-
5	D7-27 (298-304)	ACTGGGG	-N.A-	-N.A-	-N.A-	-N.A-
1	D1-7 (292-300)	TGGAACACTAC	-N.A-	-N.A-	-N.A-	-N.A-

Ab No	#N's	N	JH	J Sequence	Constant Region	CDR1
3	5	ACCCC	JH6B (321-379)	CTACTA	IGHG4 (380-565)	67-96
4	8	CTACGGCC	JH6B (367-409)	ATGGAC	IGHG1 (410-425)	136-165
2	5	CCCTC	JH6B (327-385)	CTACTA	IGHG2 (386-1362)	76-105
5	0		JH4B (305-352)	ACTACT	IGHG4 (353-541)	76-111
1	4	GGGG	JH3B (305-352)	ATGCTT	IGHG2 (353-1329)	76-105

Ab No	CDR2	CDR3	CDR1 AA Seq	CDR2 AA Seq
3	139-189	286-345	GFTFSNYGIH (SEQ ID NO:57)	VIWYDGNKYYADSVKG (SEQ ID NO:62)
4	208-258	355-375	GFTFSCYGMH (SEQ ID NO:58)	VIWYDGSNKYYADSVKG (SEQ ID NO:63)
2	148-198	295-351	GYTLTELSMH (SEQ ID NO:59)	GFDPEDGETIYAQMFQG (SEQ ID NO:64)
5	154-201	298-318	GDSISSGGHYWS (SEQ ID NO:60)	YIYYSGSSYYNPSLKS (SEQ ID NO:65)
1	148-195	292-318	GGISISIIYWS (SEQ ID NO:61)	YIYYSGSTNYNPSLKS (SEQ ID NO:66)

Ab No	CDR3 AA Seq
3	GGYYDSRGYYTPYYYYGMDV (SEQ ID NO:67)
4	GATAMDV (SEQ ID NO:68)
2	GTYYDILTGPSYYYYGLGV (SEQ ID NO:69)
5	TGDYFDY (SEQ ID NO:70)
1	WNYGDAFDI (SEQ ID NO:71)

16 / 24

FIG. 16A

> GL001H8_7_1N1k

GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCAT
CTGTAGGAGACAGAGTCACCATCACTTGTTCGGGCGAGTCA
GGGTATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCA
GGGAAAGCCCCTAAGCTCCTGATCTATGTTGCATCCAGTT
TACAAAGTGGAGTCCCATCAAGGTTTTCAGCGGCAGTGGATC
TGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCT
GAAGATATTGCAACTTACTATTGTCAACAGGCTGACAGTT
TCCCCCGGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
TCTGATGAGCAGTTGAAATCTGGAAGTGCCTGTGTTGTGT
GCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
GTGGAAGGTGGATAACGCCCTCACA (SEQ ID NO:01)

> GL001H8_7_1N1G4.txt

CAGGTGCAGCTGGAGCAGTCGGGCCCAGGACTGGTGAAGC
CTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGA
CTCCATCAGCAGTGGTGGTCACTACTGGAGCTGGATCCGC
CAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCT
ATTACAGTGGGAGTTCCTACTACAACCCGTCCCTCAAGAG
TCGATTTACCATATCAGTCGACACGTCTAAGAACCAGTTC
TCCCTGAAGCTGACCTCTGTGACTGCCGCGGACACGGCCG
TGTATTATTGTGCGAGAAGTGGGGACTACTTTGACTACTG
GGGCCTGGGAACCCTGGTCCCGTCTCCTCAGCTTCCACC
AAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGA
GCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAA
GGACTACTTCCCCGAACCGGTGACGGTGTCTGTTGGAAGTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCCTCAGGACTCTACT (SEQ ID NO:03)

> GL001H8_14_1N1K

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCA
GAACATTAGCAGTTTTTTAAATTGGTATCAGCAGAAATCA
GGGAAAGCCCCTAAGCTCCTGATCTTTGCTACATCCCGTT
TACAAAGTGGGGTCCCATCAAGGATCAGTGGCAGTGGATC
TGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCT
GAAGATTTTTCGACTTTTCTACTGTCAACAGAGTTACAGTA
TTCCACTCACTTTCGGCGGAGGGACCAAGGTGGACATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
TCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGT
GCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
GTGGAAGGTGGATAACGCCCTCA (SEQ ID NO:05)

17 / 24

FIG. 16B

> GL001H8_14_1N1G4.txt

CAGGAGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGT
CCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAG
TAACTATGGCATACTGGGTCCGCCAGGCTCCAGGCAAG
GGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAATA
ATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT
CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATG
AACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTG
CGAGAGGGGGTACTATGATAGTCGTGGTTATTACACCCC
CTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACC
ACGGTCACCGTCTCCTCAGCTTCACCAAGGGCCCATCCG
TCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAG
CACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTTCGTGGAAGTCAAGGCGCCCTGACCA
GCGGCGTGCACACCTTCCC GGCTGTCTACAGTCTCAGG
ACTCTCTC (SEQ ID NO:07)

> GL001H8_11_1N1K.txt

CAGTCTCTGGGGCTCCTGCTGCTCTGGCTCTCAGGTGCCA
GATGTGACATCCAGATGACCCAGTCTCCATCCTCCCTGTC
TGCATCTGTAGGAGACAGAGTACCATCACTTGCCAGGCG
AGTCAGGACATTAGCAACTATTTAAATTGGTATCAGCAGA
AACCAGGGAAAGCCCCCTAAGCTCCTGATCTACGATGCATC
CACTTTGAAACAGGGGTCCCATCAAGGTTCAAGTGAAGT
GGATCTGGGACAGATTTTACTTTTACCATCAGCAGCCTGC
AGCCTGAAGATATTGCAACATATTACTGTCAAACTATGA
TAATCTCCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAG
ATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCC
CGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGT
TGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAA
GTACAGTGAAGGTGGATAACGCCCTCCCAATCG (SEQ ID NO:09)

> GL001H8_11_1N1G2.txt

CCATGGAAGTTGGGGCTGAGCTGGGTTTTCTCGTTGCTC
TTTTAAGAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTC
TGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC
TCCTGTGCAGCGTCTGGATTCACCTTCAGTTGCTATGGCA
TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTG
GGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTATATTACTGTGCCGGGGGAGCT
ACGGCCATGGACGTCTGGGGCCAAGGGACCACGGTCACCG
TCTCCTCAGCCTCCACCAAGGGCCC (SEQ ID NO:11)

18 / 24

FIG. 16C

```
> GL001H1_6_2_1N1K
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACAGAGTCACCAGCACTTGCCGGGCGAGTCA
GGACATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCA
GGGAAAGTTCCTAAGCTCCTGATCTATGCTGCATCCACTT
TGCAATCAGGGGTCCCATCTCGGTTCAGTGGCAGTGGATC
TGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCT
GAAGATGTTGCAACTTATTACTGTCAAAGTATAACAGTG
CCCCGTGGACGTTCCGCCAAGGGACCAAGGTGGAAATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
TCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGT
GCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG
GAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACA
GCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGA
GAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGC
CTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT
GT (SEQ ID NO:13)
```

19 / 24

FIG. 16D

```
> GL001H1_6_2_1N1G2
CAGGTCCAGCTGGTACAGTCGGGGGCTGAGGTGAAGAAGC
CTGGGGCCTCAGTGAAGGTCTCCTGCAAGGTTTCCGGATA
CACCCTCACTGAATTATCCATGCACTGGGTGCGACAGGCT
CCTGGAAAAGGGCTTGAGTGGATGGGAGGTTTTGATCCTG
AAGATGGTGAAACAATCTACGCACAGATGTTCCAGGGCAG
AGTCACCATGACCGAGGACACATCTACAGACACAGCCTAC
ATGGACCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGT
ATTACTGTGCAACCGGAACGTATTACGATATTTTACTGG
TCCCTCCTACTACTACTACGGTTTGGGCGTCTGGGGCCAA
GGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCC
CATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTC
CGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTAC
TTCCCCGAACCGGTGACGGTGTCTGGAACCTCAGGCGCTC
TGACCAGCGGCGTGCACACCTTCCCAGCTGTCTACAGTC
CTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAG
ATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGA
GCGCAAATGTTGTGTGAGTGCCACCGTGCCAGCACCA
CCTGTGGCAGGACCGTCAGTCTTCCCTTCCCCCAAAC
CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCAC
GTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTC
CAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG
CCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTT
CCGTGTGGTCAGCGTCTCACC GTTGTGCACCAGGACTGG
CTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAG
GCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAACCAA
AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCA
TCCCGGGAGGAGATGACCAAGAACCAGGTGAGCCTGACCT
GCCTGGTCAAAGGCTTCTACCCAGCGACATCGCCGTGGA
GTGGGAGAGCAATGGGCAGCCGGAGAACA ACTACAAGACC
ACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTCTCT
ACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG
GAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
AACCCTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA
AA (SEQ ID NO:15)
```

20 / 24

FIG. 16E

```
> GL001H1_12_1_1N1K
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAT
CTGTAGGAGACAGAGTCACCATCACTTGCCGGGCGAGTCA
GGGCATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCA
GGGAAAGTTCCTAAGCTCCTGATCTATGCTGCATCCACTT
TGCAATCAGGGGTCCCATCTCGGTTTCAGTGGCAGTGGATC
TGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCT
GAAGATGTTGCAACTTATTACTGTCAAAAGTATGACAGTG
CCCCGTGGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAA
ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
TCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGT
GCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA
GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG
GAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA
GCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGA
GAAACACAAAGTCTACGCCCTGCGAAGTCACCCATCAGGGC
CTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT
GT (SEQ ID NO:17)
```

21 / 24

FIG. 16F

```
> GL001H1_12_1_1N1G2
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGC
CTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGG
CTCCATCAGTATTTACTACTGGAGCTGGATCCGGCAGCCC
CCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACA
GTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGT
CACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTG
AAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATT
ACTGTGCGGTTTGGAACTACGGGGATGCTTTTGATATCTG
GGGCCAAGGGACAATGGTCACCGTCTCTTCAGCCTCCACC
AAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGA
GCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTCCCCGAACCGGTGACGGTGTCTGGAAGTCA
GGCGCTCTGACCAGCGCGTGCACACCTTCCAGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGC
CGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGC
AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGA
CAGTTGAGCGCAAATGTTGTGTGAGTGGCCACCGTGGCC
AGCACCACTGTGGCAGGACCGTCAGTCTTCCCTTCCCC
CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCACA
GCACGTTCCGTGTGGTCAAGCTCCTCACCGTTGTGCACCA
GGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCC
AACAAAGGCCTCCCAGCCCCATCGAGAAAACCATCTCCA
AAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCT
GCCCCCATCCCGGAGGAGATGACCAAGAACCAGGTGAGC
CTGACCTGCCTGGTCAAAGGCTTCTACCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATA
CAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTC
TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC
AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC
TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
CCGGGTAAAA (SEQ ID NO:19)
```

22 / 24

FIG. 17A

> GL001H8_7_1N1k
DIQMTQSPSSVSASVGDRVITITCRASQGIS
SWLAWYQQKPGKAPKLLIYVASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDIATYYCQQ
ADSFPRTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTACVVCLLNNFYPREAKVQWKV
DNALT (SEQ ID NO:02)

> GL001H8_7_1N1G4.txt
QVQLEQSGPGLVKPSQTLSTCTVSGDSIS
SGGHYWSWIRQHPGKLEWIGYIYSGSSY
YNPSLKSRTISVDTSKNQFSLKLTSTVTA
DTAVYYCARTGDYFDYWGLGTLVTVSSAST
KGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLY
(SEQ ID NO:04)

> GL001H8_14_1N1K
DIQMTQSPSSLSASVGDRVITITCRASQNIS
SFLNWIYQQKSGKAPKLLIFATSRLQSGVPS
RISGSGSGTDFTLTISGLQPEDFATFYCQQ
SYSIPLTFGGGTKVDIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNAL (SEQ ID NO:06)

> GL001H8_14_1N1G4.txt
QEESGGGVVQPGRSLRLSCAASGFTFS
NYGIHWVRQAPGKLEWVAVIWDGNNKYY
ADSVKGRFTISRDNKNTLYLQMNSLRAED
TAVYYCARGGYDSRGYYTPYYYYGMDVWG
QGTTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLS (SEQ ID NO:08)

> GL001H8_11_1N1K.txt
QLLGLLLLWLSGARCDIQMTQSPSSLSASV
GDRVITITCQASQDISNYLNWIYQQKPGKAPK
LLIYDASTLETGVPSRFSGSGSGTDFTFI
SSLQPEDIATYYCQNYDNLPLTFGGGTKVE
IKRTVAAPSVFIFPPSDEQLKSGTASVVCL
LNNFYPREAKVQWKVDNALPI (SEQ ID NO:10)

23 / 24

FIG. 17B

> GL001H8_11_1N1G2.txt
PWKLGLSWVFLVALLRQVQCQVQLVESGGG
VVQPGRSLRLSCAASGFTFSCYGMHWVRQA
PGKGLEWVAVIWDGNSKYYADSVKGRFTI
SRDNSKNTLYLQMNSLRAEDTAVYYCAGGA
TAMDVWGQGT'TVTVSSASTKG (SEQ ID NO:12)

> GL001H1_6_2_1N1K
DIQMTQSPSSLSASVGDRVTSTCRASQDIS
NYLAWYQQKPGKVPKLLIYAASSTLQSGVPS
RFGSGSGTDF'TLTISLQPEDVATYYCQK
YNSAPWTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDYSLSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFN
RGEC (SEQ ID NO:14)

> GL001H1_6_2_1N1G2
QVQLVQSGAEVKKPGASVKVSCVSGYTTLT
ELSMHWVRQAPGKGLEWMGGFDPEDGETIY
AQMFGQGRVTMTEDTSTDTAYMDLSSLRSED
TAVYYCATGTYDILTGPSYYYYGLGVWGQ
GTTVTVSSASTKGPSVFPLAPCSRSTSEST
AALGCLVKDYFPEPVTVSWNSGALTSGVHT
FPAVLQSSGLYSLSSVTVTPSSNFGTQTYT
CNVDHKPSNTKVDKTVKCCVECPKCPAP
PVAGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVQFNWYVDGVEVHNAKTKPRE
EQFNSTFRVSVLTVVHQDWLNGKEYKCKV
SNKGLPAPIEKTISKTKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTTPMLDSGDSFFLYSKLTVD
KSRWQQGNVVFSCSVMEALHNHYTQKSLSL
SPGK (SEQ ID NO:16)

> GL001H1_12_1_1N1K
DIQMTQSPSSLSASVGDRVTITCRASQGIS
NYLAWYQQKPGKVPKLLIYAASSTLQSGVPS
RFGSGSGTDF'TLTISLQPEDVATYYCQK
YDSAPWTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDYSLSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFN
RGEC (SEQ ID NO:18)

SUBSTITUTE SHEET (RULE 26)

24 / 24

FIG. 17C

> GL001H8_11_1N1G2.txt
PWKLGLSWVFLVALLRGVQCQVQLVESGGG
VVQPGRSLRLSCAASGFTFSCYGMHWVRQA
PGKGLEWVAVIWYDGSNKYYADSVKGRFTI
SRDNSKNTLYLQMNSLRAEDTAVYYCAGGA
TAMDVWGQGT'TVTVSSASTKG (SEQ ID NO:12)

> GL001H1_6_2_1N1K
DIQMTQSPSSLSASVGDRVTSTCRASQDIS
NYLAWYQQKPGKVPKLLIYAASLQSGVPS
RFGSGSGTDFTLTISLQPEDVATYYCQK
YNSAPWTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDYSLSSSTLT
LSKADYEKHKVYACEVTHQGLSPVTKSFN
RGEC (SEQ ID NO:14)

> GL001H1_6_2_1N1G2
QVQLVQSGAEVKKPGASVKVSCKVSGYTLT
ELSMHWVRQAPGKGLEWMGGFDPEDGETIY
AQMFGQGRVTMTEDTSTDTAYMDLSSLRSED
TAVYYCATGTYYDILTGPSYYYGLGVWGQ
GTTVTVSSASTKGPSVFPLAPCSRSTSEST
AALGCLVKDYFPEPVTVSWNSGALTSGVHT
FPAVLQSSGLYSLSSVTVPSNFNGTQTYT
CNVDHKPSNTKVDKTKVERKCCVECPPEP
PVAGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVQFNWYVDGVEVHNAKTKPRE
EQFNTFRVSVLTVVHQDWLNGKEYKCKV
SNKGLPAPIEKTIISKTKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPMLDSDGSFFLYSKLTVD
KSRWQQGNVFSVCSVMHEALHNHYTQKLSL
SPGK (SEQ ID NO:16)

> GL001H1_12_1_1N1K
DIQMTQSPSSLSASVGDRVTITCRASQGIS
NYLAWYQQKPGKVPKLLIYAASLQSGVPS
RFGSGSGTDFTLTISLQPEDVATYYCQK
YDSAPWTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDYSLSSSTLT
LSKADYEKHKVYACEVTHQGLSPVTKSFN
RGEC (SEQ ID NO:18)

SEQUENCE LISTING

<110> GADI GAZIT-BORNSTEIN
 GIORGIO SENALDI
 XIAO-DONG YANG
 BRUCE KEYT
 GERARDO ZAPATA

<120> ANTI-PROPERDIN ANTIBODIES, AND METHODS
 FOR MAKING AND USING THE SAME

<130> ABGX-005WO

<140> Unassigned
 <141> 2005-11-01

<150> 10/981,300
 <151> 2004-11-03

<160> 71

<170> FastSEQ for Windows Version 4.0

<210> 1
 <211> 465
 <212> DNA
 <213> homo sapien

<400> 1
 gacatccaga tgaccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgtc gggcgagtca gggattagc agttggtag cctggatca gcagaaacca 120
 gggaaagccc ctaagctcct gatctatgtt gcatccagtt tacaaagtgg agtcccatca 180
 aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
 gaagatattg caacttacta ttgtcaacag gctgacagtt tccccggac gttcggccaa 300
 gggaccaagg tggaaatcaa acgaactgtg gctgcacat ctgtcttcat cttcccgcca 360
 tctgatgagc agttgaaatc tggaactgcc tgtgttgtgt gcctgctgaa taacttctat 420
 cccagagagg ccaaagtaca gtggaagggtg gataacgccc tcaca 465

<210> 2
 <211> 155
 <212> PRT
 <213> homo sapien

<400> 2
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Val Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ala Asp Ser Phe Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Cys Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Thr
 145 150 155

<210> 3
 <211> 541
 <212> DNA
 <213> homo sapien

<400> 3
 caggtgcagc tggagcagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60
 acctgcactg tctctgggtga ctccatcagc agtgggtggtc actactggag ctggatccgc 120
 cagcaccag ggaagggcct ggagtggatt ggtacatct attacagtgg gagttcctac 180
 tacaaccggt ccctcaagag tcgatttacc atatcagtcg acacgtctaa gaaccagttc 240
 tccctgaagc tgacctctgt gactgccgcg gacacggccg tgtattattg tgcgagaact 300
 ggggactact ttgactactg gggcctggga accctgggtca cctgtctcctc agcttccacc 360
 aagggcccat ccgtcttccc cctggcgccc tgctccagga gcacctccga gagcacagcc 420
 gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacgggtgtc gtggaactca 480
 ggcgcctga ccagcggcgt gcacaccttc ccggctgtcc tacagtctc aggactctac 540
 t 541

<210> 4
 <211> 180
 <212> PRT
 <213> homo sapien

<400> 4
 Gln Val Gln Leu Glu Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Gly
 20 25 30
 Gly His Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Ser Tyr Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Phe Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80
 Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Thr Gly Asp Tyr Phe Asp Tyr Trp Gly Leu Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
 115 120 125
 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
 130 135 140
 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
 145 150 155 160
 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
 165 170 175
 Ser Gly Leu Tyr
 180

<210> 5
 <211> 463
 <212> DNA
 <213> homo sapien

<400> 5
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60

atcacttgcc gggcaagtca gaacattagc agttttttaa attggtatca gcagaaatca 120
 gggaaagccc ctaagctcct gatctttgct acatcccgtt tacaaaagtgg ggtcccatca 180
 aggatcagtg gcagtgatc tgggacagat ttcactctca ccatcagcgg tctgcaacct 240
 gaagattttg cgactttcta ctgtcaacag agttacagta ttccactcac tttcggcgga 300
 gggaccaagg tggacatcaa acgaactgtg gctgcacat ctgtcttcat cttcccgcga 360
 tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
 cccagagagg ccaaagtaca gtggaagggt gataacgccc tca 463

<210> 6
 <211> 154
 <212> PRT
 <213> homo sapien

<400> 6
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Ser Ser Phe
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Phe Ala Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Ile Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Phe Tyr Cys Gln Gln Ser Tyr Ser Ile Pro Leu
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu
 145 150

<210> 7
 <211> 568
 <212> DNA
 <213> homo sapien

<400> 7
 caggagcagt ctgggggagg cgtggtccag cctgggaggt ccctgagact ctctgtgca 60
 gcgtctggat tcacottcag taactatggc atacactggg tccgccaggc tccaggcaag 120
 gggctggagt ggggtggcagt tatatggtat gatggaaata ataaatacta tgcagactcc 180
 gtgaagggcc gattcaccat ctccagagac aattccaaga acacgctgta tctgcaaatg 240
 aacagcctga gagccgagga cacggctgtg tattactgtg cgagaggggg ttactatgat 300
 agtcgtgggtt attacacccc ctactactac tacggatgg acgtctgggg ccaagggacc 360
 acggtcaccg tctcctcagc ttccaccaag ggcccatccg tcttccccct ggcgcccctgc 420
 tccaggagca cctccgagag cacagccgcc ctgggctgcc tggtaagga ctacttcccc 480
 gaaccgggtga cgggtgctgtg gaactcaggc gccctgacca gggcgctgca caccttcccg 540
 gctgtcctac agtcctcagg actctctc 568

<210> 8
 <211> 189
 <212> PRT
 <213> homo sapien

<400> 8
 Gln Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg
 1 5 10 15

Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Ile His
 20 25 30
 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile
 35 40 45
 Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg
 50 55 60
 Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
 65 70 75 80
 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly
 85 90 95
 Gly Tyr Tyr Asp Ser Arg Gly Tyr Tyr Thr Pro Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser
 115 120 125
 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
 130 135 140
 Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
 145 150 155 160
 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
 165 170 175
 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Ser
 180 185

<210> 9
 <211> 514
 <212> DNA
 <213> homo sapien

<400> 9
 cagctcctgg ggctcctgct gctctggctc tcaggtgcca gatgtgacat ccagatgacc 60
 cagtctccat cctccctgtc tgcattctgta ggagacagag tcaccatcac ttgccaggcg 120
 agtcaggaca ttagcaacta tttaaattgg tatcagcaga aaccagggaa agcccctaag 180
 ctctgatct acgatgcac cactttggaa acaggggtcc catcaagggt cagtggaagt 240
 ggatctggga cagattttac tttcaccatc agcagcctgc agcctgaaga tattgcaaca 300
 tattactgtc aaaactatga taatctccct ctcaatttcg gcggaggggac caaggtggag 360
 atcaaacgaa ctgtggtctg accatctgtc ttcattctcc cgccatctga tgagcagttg 420
 aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa 480
 gtacagtgga aggtggataa cgccctccca atcg 514

<210> 10
 <211> 171
 <212> PRT
 <213> homo sapien

<400> 10
 Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Ser Gly Ala Arg Cys Asp
 1 5 10 15
 Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
 20 25 30
 Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu
 35 40 45
 Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 50 55 60
 Asp Ala Ser Thr Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser
 65 70 75 80
 Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu
 85 90 95
 Asp Ile Ala Thr Tyr Tyr Cys Gln Asn Tyr Asp Asn Leu Pro Leu Thr
 100 105 110
 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro

	115					120						125			
Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
	130					135					140				
Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
145					150					155					160
Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Pro	Ile					
				165					170						

<210> 11
 <211> 425
 <212> DNA
 <213> homo sapien

<400> 11
 ccatggaagt tggggctgag ctgggttttc ctcgttgctc ttttaagagg tgtccagtgt 60
 cagggtgcagc tgggtggagtc tgggggaggc gtggtccagc ctggggaggc cctgagactc 120
 tcctgtgcag cgtctggatt caccttcagt tgctatggca tgcactgggt ccgccaggct 180
 ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaatactat 240
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 300
 ctgcaaatga acagcctgag agccgaggac acggctgtat attactgtgc cgggggagct 360
 acggccatgg acgtctgggg ccaagggacc acggtcaccg tctcctcagc ctccaccaag 420
 ggccc 425

<210> 12
 <211> 141
 <212> PRT
 <213> homo sapien

<400> 12
 Pro Trp Lys Leu Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg
 1 5 10 15
 Gly Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val
 20 25 30
 Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
 35 40 45
 Phe Ser Cys Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
 50 55 60
 Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr
 65 70 75 80
 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
 85 90 95
 Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
 100 105 110
 Val Tyr Tyr Cys Ala Gly Gly Ala Thr Ala Met Asp Val Trp Gly Gln
 115 120 125
 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
 130 135 140

<210> 13
 <211> 642
 <212> DNA
 <213> homo sapien

<400> 13
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 agcacttgcc gggcgagtca ggacattagc aattatntag cctgggtatca gcagaaacca 120
 gggaaagttc ctaagctcct gatctatgct gcatccactt tgcaatcagg ggtcccctct 180
 cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
 gaagatgttg caacttatta ctgtcaaaag tataacagtg ccccgtggac gttcggccaa 300
 gggaccaagg tggaaatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcga 360

```
tctgatgagc agttgaaatc tggaactgcc tctgtttgtg gcttgcctgaa taactttctat 420
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 480
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642
```

<210> 14
 <211> 214
 <212> PRT
 <213> homo sapien

<400> 14

```
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ser Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
           20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
           35           40           45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
           50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Trp
           85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
           100          105          110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
           115          120          125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
           130          135          140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145          150          155          160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
           165          170          175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
           180          185          190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
           195          200          205
Phe Asn Arg Gly Glu Cys
           210
```

<210> 15
 <211> 1362
 <212> DNA
 <213> homo sapien

<400> 15

```
caggtccagc tggtagcagc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg tttccggata caccctcact gaattatcca tgcactgggt gcgacaggct 120
cctggaaaag ggcttgagtg gatgggaggt tttgatcctg aagatgggtg aacaatctac 180
gcacagatgt tccagggcag agtcaccatg accgaggaca catctacaga cacagcctac 240
atggacctga gcagcctgag atctgaggac acggccgtgt attactgtgc aaccggaacg 300
tattacgata ttttgactgg tcacctctac tactactacg gtttgggcgt ctggggccaa 360
gggaccacgg tcaccgtctc ctcagcctcc accaagggcc catcgggtctt ccccctggcg 420
ccctgctcca ggagcacctc cgagagcaca ggggccctgg gctgcctggg caaggactac 480
ttcccgaac cgggtgacggg gtcgtggaac tcaggcgctc tgaccagcgg cgtgcacacc 540
ttcccagctg tcctacagtc ctcaggactc tactcctca gcagcgtggg gaccgtgccc 600
tccagcaact tcggcaccca gacctacacc tgcaacgtag atcacaagcc cagcaacacc 660
aaggtggaca agacagttga gcgcaaatgt tgtgtcgagt gccaccgtg cccagcacca 720
cctgtggcag gaccgtcagt cttcctcttc ccccaaaaac ccaaggacac cctcatgatc 780
tcccggacc ctgaggtcac gtgcgtggtg gtggacgtga gccacgaaga ccccgaggtc 840
```

cagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccacgggag 900
 gagcagttca acagcacggt ccgtgtggtc agcgtcctca ccgttgtgca ccaggactgg 960
 ctgaacggca aggagtacaa gtgcaaggtc tccaacaaag gcctcccagc ccccatcgag 1020
 aaaaccatct ccaaaaccaa agggcagccc cgagaaccac aggtgtacac cctgccccca 1080
 tcccggggagg agatgaccaa gaaccaggtc agcctgacct gcctgggtaa aggtttctac 1140
 cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc 1200
 acacctccca tgctggactc cgacggctcc ttcttctctt acagcaagct caccgtggac 1260
 aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac 1320
 aaccactaca cgcagaagag cctctccctg tctccgggta aa 1362

<210> 16

<211> 454

<212> PRT

<213> homo sapien

<400> 16

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
 20 25 30
 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Met Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
 65 70 75 80
 Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Thr Gly Thr Tyr Tyr Asp Ile Leu Thr Gly Pro Ser Tyr Tyr Tyr
 100 105 110
 Tyr Gly Leu Gly Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125
 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 130 135 140
 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 145 150 155 160
 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 165 170 175
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 180 185 190
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
 195 200 205
 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 210 215 220
 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
 225 230 235 240
 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
 245 250 255
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
 260 265 270
 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
 275 280 285
 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
 290 295 300
 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
 305 310 315 320
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 325 330 335
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
 340 345 350
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 355 360 365

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 370 375 380
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 385 390 395 400
 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 405 410 415
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 420 425 430
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 435 440 445
 Ser Leu Ser Pro Gly Lys
 450

<210> 17
 <211> 642
 <212> DNA
 <213> homo sapien

<400> 17
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcgagtc gggcattagc aattatttag cctggatca gcagaaacca 120
 gggaaagttc ctaagctcct gatctatgct gcatccactt tgcaatcagg ggtcccatct 180
 cggttcagtg gcagtgatc tgggacagat ttcactctca ccacagcag cctgcagcct 240
 gaagatgttg caacttatta ctgtcaaaag tatgacagtg ccccgtaggac gttcggccaa 300
 gggaccaagg tggaaatcaa acgaactgtg gctgcacat ctgtcttcat cttcccgcc 360
 tctgatgagc agttgaaatc tggaaactgcc tctgttgtgt gcctgctgaa taacttctat 420
 cccagagagg ccaaagtaca gtggaaggtg gataacgcc tccaatcggg taactcccag 480
 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
 ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccacagggc 600
 ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642

<210> 18
 <211> 214
 <212> PRT
 <213> homo sapien

<400> 18
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asp Ser Ala Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Cys
 210

<210> 19
 <211> 1330
 <212> DNA
 <213> homo sapien

<400> 19
 cagggtgcagc tgcaggagtc gggcccagga ctgggtgaagc cttcggagac cctgtccctc 60
 acctgcactg tctctgggtg ctccatcagt atttactact ggagctggat ccggcagccc 120
 ccaggggaagg gactggagtg gattgggtat atctattaca gtgggagcac caactacaac 180
 ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
 aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcggt ttggaactac 300
 ggggatgctt ttgatatctg gggccaaggg acaatgggtca ccgtctcttc agcctccacc 360
 aagggcccat cggctcttccc cctggcgccc tgctccagga gcacctccga gagcacagcg 420
 gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacgggtgtc gtggaactca 480
 ggcgctctga ccagcggcgt gcacaccttc ccagctgtcc tacagtctc aggactctac 540
 tccctcagca gcgtgggtgac cgtgccctcc agcaacttcg gcaccagac ctacacctgc 600
 aacgtagatc acaagcccag caacaccaag gtggacaaga cagttgagcg caaatgttgt 660
 gtcgagtgcc caccgtgccc agcaccacct gtggcaggac cgtcagtctt cctcttcccc 720
 ccaaaaccca aggacaccct catgatctcc cggaccctg aggtcacgtg cgtgggtgtg 780
 gacgtgagcc agcaagacc cagaggtccag ttcaactggt acgtggacgg cgtggagggtg 840
 cataatgccca agacaaagcc acgggaggag cagttcaaca gcacgttccg tgtggtcagc 900
 gtcctcaccg ttgtgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 960
 aacaaaggcc tcccagcccc catcgagaaa accatctcca aaaccaaagg gcagccccga 1020
 gaaccacagg tgtacaccct gccccatcc cgggaggaga tgaccaagaa ccaggtcagc 1080
 ctgacctgcc tgggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1140
 gggcagccgg agaacaacta caagaccaca cctcccagtc tggactccga cggctccttc 1200
 ttctcttaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 1260
 tgctccgtga tgcattgagc tctgcacaac cactacacgc agaagagcct ctccctgtct 1320
 ccgggtaaaa 1330

<210> 20
 <211> 443
 <212> PRT

<213> homo sapien

<400> 20
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ile Tyr
 20 25 30
 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60
 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80
 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Val Trp Asn Tyr Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
 100 105 110
 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
 115 120 125
 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys

	130					135						140					
Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser		
145					150					155					160		
Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser		
				165					170					175			
Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Asn		
			180					185					190				
Phe	Gly	Thr	Gln	Thr	Tyr	Thr	Cys	Asn	Val	Asp	His	Lys	Pro	Ser	Asn		
		195					200					205					
Thr	Lys	Val	Asp	Lys	Thr	Val	Glu	Arg	Lys	Cys	Cys	Val	Glu	Cys	Pro		
	210					215						220					
Pro	Cys	Pro	Ala	Pro	Pro	Val	Ala	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro		
225					230						235				240		
Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr		
				245					250					255			
Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn		
			260					265					270				
Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg		
	275						280					285					
Glu	Glu	Gln	Phe	Asn	Ser	Thr	Phe	Arg	Val	Val	Ser	Val	Leu	Thr	Val		
	290					295					300						
Val	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser		
305					310					315					320		
Asn	Lys	Gly	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Thr	Lys		
				325					330					335			
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu		
			340					345					350				
Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe		
		355					360					365					
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu		
	370					375					380						
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Met	Leu	Asp	Ser	Asp	Gly	Ser	Phe		
385					390					395					400		
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly		
				405					410					415			
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr		
			420					425					430				
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys							
		435					440										

<210> 21
 <211> 108
 <212> PRT
 <213> homo sapien

<400> 21
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 22
 <211> 108
 <212> PRT
 <213> homo sapien

<400> 22
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asp Ser Ala Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 23
 <211> 108
 <212> PRT
 <213> homo sapien

<400> 23
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ser Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asp Ser Ala Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 24
 <211> 105
 <212> PRT
 <213> homo sapien

<400> 24
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Phe Gly

85 90 95
 Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 25
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 25
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Ser Ser Phe
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Phe Ala Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Ile Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Phe Tyr Cys Gln Gln Ser Tyr Ser Ile Pro Leu
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Asp Ile Lys Arg
 100 105

<210> 26
 <211> 106
 <212> PRT
 <213> homo sapiens

<400> 26
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Thr Phe
 85 90 95
 Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 27
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 27
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Val Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ala Asp Ser Phe Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 28
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 28
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 29
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 29
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asp Ala Ser Thr Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Asn Tyr Asp Asn Leu Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 30
 <211> 11
 <212> PRT
 <213> homo sapiens

<400> 30
 Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala

1 5 10

<210> 31
<211> 11
<212> PRT
<213> homo sapiens

<400> 31
Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Ala
1 5 10

<210> 32
<211> 11
<212> PRT
<213> homo sapiens

<400> 32
Arg Ala Ser Gln Asn Ile Ser Ser Phe Leu Asn
1 5 10

<210> 33
<211> 11
<212> PRT
<213> homo sapiens

<400> 33
Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> 34
<211> 11
<212> PRT
<213> homo sapiens

<400> 34
Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10

<210> 35
<211> 7
<212> PRT
<213> homo sapiens

<400> 35
Ala Ala Ser Thr Leu Gln Ser
1 5

<210> 36
<211> 7
<212> PRT
<213> homo sapiens

<400> 36
Ala Ala Ser Thr Leu Gln Ser
1 5

<210> 37
<211> 7
<212> PRT
<213> homo sapiens

<400> 37
Ala Thr Ser Arg Leu Gln Ser
1 5

<210> 38
<211> 7
<212> PRT
<213> homo sapiens

<400> 38
Asp Ala Ser Thr Leu Glu Thr
1 5

<210> 39
<211> 7
<212> PRT
<213> homo sapiens

<400> 39
Val Ala Ser Ser Leu Gln Ser
1 5

<210> 40
<211> 9
<212> PRT
<213> homo sapiens

<400> 40
Gln Lys Tyr Asp Ser Ala Pro Trp Thr
1 5

<210> 41
<211> 9
<212> PRT
<213> homo sapiens

<400> 41
Gln Lys Tyr Asn Ser Ala Pro Trp Thr
1 5

<210> 42
<211> 9
<212> PRT
<213> homo sapiens

<400> 42
Gln Gln Ser Tyr Ser Ile Pro Leu Thr
1 5

<210> 43

<211> 9
 <212> PRT
 <213> homo sapiens

<400> 43
 Gln Asn Tyr Asp Asn Leu Pro Leu Thr
 1 5

<210> 44
 <211> 9
 <212> PRT
 <213> homo sapiens

<400> 44
 Gln Gln Ala Asp Ser Phe Pro Arg Thr
 1 5

<210> 45
 <211> 126
 <212> PRT
 <213> Homo sapiens

<400> 45
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala
 115 120 125

<210> 46
 <211> 127
 <212> PRT
 <213> Homo sapiens

<400> 46
 Gln Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg
 1 5 10 15
 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Ile His
 20 25 30
 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile
 35 40 45
 Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg
 50 55 60
 Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
 65 70 75 80
 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly
 85 90 95
 Gly Tyr Tyr Asp Ser Arg Gly Tyr Tyr Thr Pro Tyr Tyr Tyr Tyr Gly

			100						105					110
Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Ala
			115						120					125

<210> 47
 <211> 113
 <212> PRT
 <213> Homo sapiens

<400> 47
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 100 105 110
 Ala

<210> 48
 <211> 117
 <212> PRT
 <213> Homo sapiens

<400> 48
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Cys Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Gly Gly Ala Thr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val
 100 105 110
 Thr Val Ser Ser Ala
 115

<210> 49
 <211> 124
 <212> PRT
 <213> Homo sapiens

<400> 49
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu

			20					25					30			
Ser	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	
		35					40					45				
Gly	Gly	Phe	Asp	Pro	Glu	Asp	Gly	Glu	Thr	Ile	Tyr	Ala	Gln	Lys	Phe	
		50				55					60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Glu	Asp	Thr	Ser	Thr	Asp	Thr	Ala	Tyr	
65					70					75					80	
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85					90					95		
Ala	Tyr	Tyr	Asp	Ile	Leu	Thr	Gly	Tyr	Tyr	Tyr	Tyr	Gly	Met	Asp	Val	
			100					105					110			
Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Ala					
		115					120									

<210> 50
 <211> 129
 <212> PRT
 <213> Homo sapiens

<400> 50

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala	
1				5					10					15		
Ser	Val	Lys	Val	Ser	Cys	Lys	Val	Ser	Gly	Tyr	Thr	Leu	Thr	Glu	Leu	
			20					25					30			
Ser	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met	
		35					40					45				
Gly	Gly	Phe	Asp	Pro	Glu	Asp	Gly	Glu	Thr	Ile	Tyr	Ala	Gln	Met	Phe	
		50				55					60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Glu	Asp	Thr	Ser	Thr	Asp	Thr	Ala	Tyr	
65					70					75					80	
Met	Asp	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85					90					95		
Ala	Thr	Gly	Thr	Tyr	Tyr	Asp	Ile	Leu	Thr	Gly	Pro	Ser	Tyr	Tyr	Tyr	
			100					105					110			
Tyr	Gly	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	
		115					120					125				

Ala

<210> 51
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 51

Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Ser	Gln	
1				5					10					15		
Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Gly	Ser	Ile	Ser	Ser	Gly	
			20					25					30			
Gly	Tyr	Tyr	Trp	Ser	Trp	Ile	Arg	Gln	His	Pro	Gly	Lys	Gly	Leu	Glu	
		35					40					45				
Trp	Ile	Gly	Tyr	Ile	Tyr	Tyr	Ser	Gly	Ser	Thr	Tyr	Tyr	Asn	Pro	Ser	
		50				55					60					
Leu	Lys	Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe	
65					70					75					80	
Ser	Leu	Lys	Leu	Ser	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	
				85					90					95		
Cys	Ala	Arg	Thr	Gly	Asp	Tyr	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	
			100					105					110			

Val Thr Val Ser Ser Ala

115

<210> 52
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 52
 Gln Val Gln Leu Glu Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Gly
 20 25 30
 Gly His Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Ser Tyr Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Phe Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80
 Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Thr Gly Asp Tyr Phe Asp Tyr Trp Gly Leu Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser Ala
 115

<210> 53
 <211> 115
 <212> PRT
 <213> Homo sapiens

<400> 53
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
 20 25 30
 Tyr Trp Ser Trp Ile Arg Gln Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
 50 55 60
 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80
 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Trp Asn Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val
 100 105 110
 Ser Ser Ala
 115

<210> 54
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 54
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ile Tyr
 20 25 30
 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile

		35					40				45				
Gly	Tyr	Ile	Tyr	Tyr	Ser	Gly	Ser	Thr	Asn	Tyr	Asn	Pro	Ser	Leu	Lys
	50					55					60				
Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser	Leu
65					70					75					80
Lys	Leu	Ser	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
				85					90					95	
Val	Trp	Asn	Tyr	Gly	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met
			100					105					110		
Val	Thr	Val	Ser	Ser	Ala										
		115													

<210> 55
 <211> 25
 <212> DNA
 <213> Homo sapiens

<400> 55
 ttactatgat agtcgtggtt attac 25

<210> 56
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 56
 gtattacgat attttgactg gt 22

<210> 57
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 57
 Gly Phe Thr Phe Ser Asn Tyr Gly Ile His
 1 5 10

<210> 58
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 58
 Gly Phe Thr Phe Ser Cys Tyr Gly Met His
 1 5 10

<210> 59
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 59
 Gly Tyr Thr Leu Thr Glu Leu Ser Met His
 1 5 10

<210> 60
 <211> 12
 <212> PRT

<213> Homo sapiens

<400> 60

Gly Asp Ser Ile Ser Ser Gly Gly His Tyr Trp Ser
 1 . 5 10

<210> 61

<211> 10

<212> PRT

<213> Homo sapiens

<400> 61

Gly Gly Ser Ile Ser Ile Tyr Tyr Trp Ser
 1 5 10

<210> 62

<211> 17

<212> PRT

<213> Homo sapiens

<400> 62

Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15
 Gly

<210> 63

<211> 17

<212> PRT

<213> Homo sapiens

<400> 63

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15
 Gly

<210> 64

<211> 17

<212> PRT

<213> Homo sapiens

<400> 64

Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Met Phe Gln
 1 5 10 15
 Gly

<210> 65

<211> 16

<212> PRT

<213> Homo sapiens

<400> 65

Tyr Ile Tyr Tyr Ser Gly Ser Ser Tyr Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 66
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 66
 Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 67
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 67
 Gly Gly Tyr Tyr Asp Ser Arg Gly Tyr Tyr Thr Pro Tyr Tyr Tyr Tyr
 1 5 10 15
 Gly Met Asp Val
 20

<210> 68
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 68
 Gly Ala Thr Ala Met Asp Val
 1 5

<210> 69
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 69
 Gly Thr Tyr Tyr Asp Ile Leu Thr Gly Pro Ser Tyr Tyr Tyr Tyr Gly
 1 5 10 15
 Leu Gly Val

<210> 70
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 70
 Thr Gly Asp Tyr Phe Asp Tyr
 1 5

<210> 71
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 71
 Trp Asn Tyr Gly Asp Ala Phe Asp Ile
 1 5